,line,label
0,"Standard limbus-based trabeculectomy with adjunct mitomycin C (0.3 mg/mL for 3 minutes) in 16 eyes of 16 patients; AIGT was performed in 16 eyes of 16 patients. The groups were matched for age, preoperative IOP, duration of preoperative antiglaucoma treatment, use of preoperative beta-blockers and parasympathomimetics, and use of beta-blockers in the fellow eye. The IOP (average of the two highest values measured in the diurnal curve, from 8 AM to 6 PM, every 2 hours) and complications were recorded 1, 3, 6, 12, 18, and 24 months after surgery.",NON-PATIENT
1,setting: Clinical practice.,NON-PATIENT
2,Two hundred unselected patients with definite or suspect glaucoma or neuro-ophthalmic VF indication participated.,PATIENT
3,"Baseline AHF was measured by computerized fluorophotometry and IOP by pneumatonometry without antiglaucoma therapy. In the first protocol, dorzolamide was randomized to one eye (N = 10) and IOP and AHF measurements were repeated. One week later, having used dorzolamide in one eye three times daily, patients had measurements performed before and after the single administration of oral acetazolamide 250 mg. In the second protocol, having used acetazolamide 250 mg four times daily for 4 to 7 days (N = 6), patients had measurements performed before and after a single drop of dorzolamide was instilled randomly into one eye. The patient continued acetazolamide and unilateral dorzolamide for 4 to 7 more days and returned for IOP and AHF measurements.",NON-PATIENT
4,"Randomized, double-masked, controlled clinical trial.",NON-PATIENT
5,Single university hospital.,NON-PATIENT
6,"This randomized clinical trial studied 222 consecutive patients undergoing trabeculectomy from October 1, 2014, through November 31, 2015, at 4 rural hospitals in Guangdong and Guangxi Provinces, China. Data from the intention-to-treat population were analyzed.",PATIENT
7,Prospective multicenter cohort study incorporating 2 natural history groups and 2 randomized controlled clinical trials.,NON-PATIENT
8,"The study was a single-center, 2-arm randomized controlled trial with 6-month follow-up.",NON-PATIENT
9,The study took place in the Oncology Day Treatment Unit of a university hospital in Turkey.,NON-PATIENT
10,Patients with open-angle glaucoma or ocular hypertension.,PATIENT
11,"Patients were randomized to platinum-based chemotherapy, concurrent with chest radiotherapy (60-63 Gy), with or without consolidation chemotherapy or the same treatment plus metformin, 2000 mg/d, during chemoradiotherapy and afterward for up to 12 months.",NON-PATIENT
12,One hundred and thirty-one subjects with NSCLC admitted for curative surgery.,PATIENT
13,A total of 335 patients with bilateral ocular hypertension or open-angle glaucoma participated.,PATIENT
14,Patients in the control group had routine postoperative percussive chest physiotherapy four times a day. Participants in the high-frequency chest wall oscillation group received three sessions of high-frequency chest wall oscillation treatment every 8 hrs for 15 mins starting 4 hrs after surgery. All the treatments and measurements were performed by randomly assigned nursing staff who had received standardized education for respiratory care and who were not aware of the details of the study.,NON-PATIENT
15,Sixty-eight patients (68 eyes) with refractory glaucomas were included in the study.,PATIENT
16,This is a single-institution randomized phase 2 study of maintenance chemotherapy alone vs SAbR followed by maintenance chemotherapy for patients with limited metastatic NSCLC (primary plus up to 5 metastatic sites) whose tumors did not possess EGFR-targetable or ALK-targetable mutations but did achieve a partial response or stable disease after induction chemotherapy.,PATIENT
17,"Intraocular pressure taken at hours 0 (trough) and 2 (peak) after week 2 and months 1, 2, and 3 was compared to baseline within each treatment group and between the combination and each component group. The safety profile of the combination was compared to each component.",NON-PATIENT
18,Cross-sectional study.,NON-PATIENT
19,Tube shunt (350-mm,NON-PATIENT
20,A total of 240 eyes with mild to moderate open-angle glaucoma with intraocular pressure (IOP) ≤24 mmHg controlled on 1 to 3 medications were randomized to undergo cataract surgery with iStent implantation (treatment group) or cataract surgery only (control). Fifty additional subjects were enrolled to undergo cataract surgery with iStent implantation under protocol expansion. Data in this report are based on the first 240 eyes enrolled.,PATIENT
21,Brimonidine was added to the existing regimen of glaucoma medication.,NON-PATIENT
22,"Four hundred eighty-three patients with glaucoma or ocular hypertension were enrolled. Of these, 463 were evaluated according to the protocol criteria (280 in the brimonidine tartrate group and 183 in the timolol group).",PATIENT
23,Patients with OAG who were younger than 65 years and had untreated IOP consistently of 16 mmHg or less.,PATIENT
24,17 Clinical Centers.,NON-PATIENT
25,Two hundred seventy-six subjects aged 18-85 years with previous intraocular surgery or refractory glaucoma with intraocular pressure of >18 mm Hg.,PATIENT
26,Primary end points were progression-free survival (PFS) for each arm and safety. Data were evaluated according to an intent-to-treat analysis.,NON-PATIENT
27,"Women with an intact uterus received conjugated equine estrogens (CEE; 0.625 mg/d) plus medroxyprogesterone acetate (MPA; 2.5 mg/d) (n = 8506) or placebo (n = 8102). Women with prior hysterectomy received CEE alone (0.625 mg/d) (n = 5310) or placebo (n = 5429). The intervention lasted a median of 5.6 years in CEE plus MPA trial and 7.2 years in CEE alone trial with 13 years of cumulative follow-up until September 30, 2010.",NON-PATIENT
28,"Intraocular pressure, visual acuity, inflammation measured by slit-lamp examination and laser flare meter, cataract grading, bleb appearance, dry eye scores, use of supplemental medical therapy, surgical success, and rate of complications.",NON-PATIENT
29,"The proportion of eyes in which the increase in IOP after washout, using the mean of the 3 measurements, differed by more than 0.5, 1.0, 1.5, or 2.0 mm Hg from the increase in IOP after washout using only 1 of the postwashout measurements. A proportion of 10% or less at the 1.5-mm Hg cutoff was considered clinically acceptable. The hypothesis was formulated after data collection but before the data were examined.",NON-PATIENT
30,"36 ASA physical status 1 and 2 patients undergoing elective, video-assisted thoracic surgery for lung tumors.",PATIENT
31,Development of advanced AMD. The unit of analyses used was by eye.,NON-PATIENT
32,"Four hundred one infants in whom prethreshold ROP developed in one or both eyes and who were randomized after they were determined to have a high risk (> or =15%) of poor structural outcome without treatment using the Risk Management of Retinopathy of Prematurity (RM-ROP2) program. Refractive error was measured by cycloplegic retinoscopy. Eyes with additional retinal, glaucoma, or cataract surgery were excluded.",PATIENT
33,"A total of 332 black patients (451 eyes), 249 white patients (325 eyes), and 10 patients of other races (13 eyes) participated. Potential follow-up ranged from 4 to 7 years.",PATIENT
34,"A prospective, randomized, double-blind, controlled trial.",NON-PATIENT
35,Triamcinolone acetonide (0.1 ml) was injected through the pars plana using a 27-gauge needle. Eyes randomized to placebo received a subconjunctival injection of saline.,NON-PATIENT
36,"After washout of any previous ocular hypotensive medications, patients were randomly assigned to treatment with bimatoprost 0.03% ophthalmic solution QD (n=38) or latanoprost 0.005% ophthalmic solution QD (n=38) between 7 and 9 pm, or timolol maleate 0.5% gel-forming ophthalmic solution QD (n=39) between 7 and 9 am for 1 month.",NON-PATIENT
37,"An 8-week, double-masked, randomized, parallel-group, single-center clinical trial.",NON-PATIENT
38,"Single-stage, prospective, noncomparative, randomized, open-label, multicenter, phase 2 study on previously untreated patients with mRCC and Eastern Cooperative Oncology Group performance status 0-2.",PATIENT
39,"Take a Break (TAB) was a 3-week game experience and included 5 behavioral components (motivational messaging, challenge quizzes, brief abstinence goal setting, mobile health apps for cravings management, and reward points for participation) integrated with NRT sampling. TAB draws on social cognitive theory and game mechanics concepts to engage participants in health behavior change. The comparison included NRT sampling only.",NON-PATIENT
40,"Intravitreal injections of aflibercept, 2 mg, every 16 weeks after 3 initial monthly doses and one 8-week interval (aflibercept 2q16 group); intravitreal injections of aflibercept, 2 mg, every 8 weeks after 5 initial monthly doses, with pro re nata (PRN) dosing beginning at week 56 (aflibercept 2q8/PRN group); or sham injections (control group).",NON-PATIENT
41,Setting: Seventeen clinical centers.,NON-PATIENT
42,Nondiabetic pseudophakic patients with definite POAG were recruited; 29 eyes of 16 individuals participated in study 1. A follow-up study (study 2) included 14 eyes of 7 individuals.,PATIENT
43,The authors made a reference to electronic records of the product sales to patients who have been made the repurchase of the Can-C eye drops since December 2001.,PATIENT
44,"Patients were randomized (2:1) to either the GAIN (intervention) or standard of care (SOC) arm. In the GAIN arm, a geriatrics-trained multidisciplinary team composed of an oncologist, nurse practitioner, social worker, physical/occupation therapist, nutritionist, and pharmacist reviewed geriatric assessment results and implemented interventions based on prespecified thresholds built into the geriatric assessment's domains. In the SOC arm, geriatric assessment results were sent to treating oncologists for consideration.",NON-PATIENT
45,"The main outcome was grade 3 or higher treatment-related adverse events (AEs) occurring within 1 year of SABR. Secondary outcomes were freedom from local failure, overall survival, disease-free survival, and patient-reported outcomes (MD Anderson Symptom Inventory-Lung Cancer and EuroQol 5-dimension visual analog scale).",NON-PATIENT
46,"The study was a randomized, controlled trial.",NON-PATIENT
47,TG: six-week threshold inspiratory muscle training and aerobic exercise. CG: standard care.,NON-PATIENT
48,Patients were randomized equally into the PORT arm (n = 202) or the observation arm (n = 192). The total dose of PORT was 50 Gy.,NON-PATIENT
49,"This multicenter, unblinded, phase 2 randomized clinical trial of 90 patients across 13 centers in Australia and New Zealand enrolled patients with 1 to 3 lung oligometastases less than or equal to 5 cm from any nonhematologic malignant tumors located away from the central airways, Eastern Cooperative Oncology Group performance status 0 or 1, and all primary and extrathoracic disease controlled with local therapy. Enrollment was from January 1, 2015, to December 31, 2018, with a minimum patient follow-up of 2 years.",PATIENT
50,"We performed a prospective cohort study of medication adherence, followed by a randomized intervention for those found to be nonadherent, of individuals recruited from a university-based glaucoma subspecialty clinic. A total of 491 participants were enrolled in the initial assessment of adherence. Of those, 70 were nonadherent with their medications after 3 months of electronic monitoring and randomized to intervention and control groups.",PATIENT
51,A total of 560 patients with primary open-angle glaucoma or ocular hypertension who had insufficient IOP reduction with their current therapeutic regimen or who were receiving ≥ 2 IOP-lowering medications.,PATIENT
52,"The QOL data were collected prospectively via FACT Trial Outcome Index (FACT-TOI), calculated as the sum of the following measures: Physical Well Being (PWB), Functional Well Being (FWB), and the LCS. Data are presented at baseline and 3 and 12 months via minimal clinically meaningful changes of 2 points or more for PWB, FWB, and LCS or 5 points or more for TOI.",NON-PATIENT
53,"Patients with advanced lung adenocarcinoma that progressed with prior EGFR-TKI treatment (other than third-generation TKI) and acquired EGFR T790M mutation were enrolled. This study comprises a lead-in part with 6 patients and a subsequent phase 2 part. In phase 2, patients were randomized to osimertinib plus bevacizumab or osimertinib alone in a 1:1 ratio.",PATIENT
54,Administration of 600 IU of natural-source vitamin E on alternate days.,NON-PATIENT
55,"Development of glaucoma and glaucoma + glaucoma suspect in operated on eyes for children up to age 5 years, plus intraocular pressure, visual acuity, and axial length at age 5 years.",NON-PATIENT
56,"Data were collected at baseline and postintervention. Sociodemographic and disease-related data were collected using the Patient Identification Form. Quantitative data were collected with the Modified Borg Dyspnea Scale (Borg scale) and the St George's Respiratory Questionnaire and through measurements of participants' heart rates, respiratory rates, oxygen saturation, and walking distance before and after the 6-mile walk test. Qualitative data were collected using the semistructured ""Patients' Views Form on Acupressure Experience.""",NON-PATIENT
57,"All-cause mortality and mortality due to cardiovascular disease, lung cancer, and other respiratory disease.",NON-PATIENT
58,"Patients were randomized (1:1) to ensartinib, 225 mg once daily, or crizotinib, 250 mg twice daily.",NON-PATIENT
59,Randomized controlled trial.,NON-PATIENT
60,Patients were given 1 drop of either apraclonidine 1% (n = 114) or pilocarpine 4% (n = 114) 15 minutes before ALT.,NON-PATIENT
61,The primary end point was the determination of the recommended phase 3 dose of plinabulin based on the days of severe neutropenia during chemotherapy cycle 1. Daily complete blood cell counts and absolute neutrophil counts were drawn during times of anticipated neutropenia during cycle 1.,NON-PATIENT
62,"A mobile phone-based, remote monitoring, advanced symptom management system (ASyMS).",NON-PATIENT
63,"Double-masked, randomized, prospective, multicenter clinical trial.",NON-PATIENT
64,Pseudophakic patients with glaucoma requiring Nd:YAG posterior capsulotomy (n = 76).,PATIENT
65,"Double-masked, randomized clinical trial.",NON-PATIENT
66,"Two multicenter, randomized clinical trials, 1 evaluating participants with central retinal vein occlusion (CRVO) and the other evaluating participants with branch retinal vein occlusion (BRVO).",NON-PATIENT
67,"A double-blind, randomised controlled study.",NON-PATIENT
68,"The CIGTS collected comprehensive QOL information that included both generic and vision-specific QOL measures. This article focuses on initial treatment group differences related to symptom reporting, as measured by a Symptom and Health Problem Checklist, and changes in daily visual functioning, as measured by the Visual Activities Questionnaire (VAQ).",NON-PATIENT
69,"Prospective, randomized, controlled 3-year trial.",NON-PATIENT
70,"Multicenter, prospective randomized clinical trial.",NON-PATIENT
71,"The primary outcome was the proportion of patients who experienced a failure event (ie, locoregional disease progression, distant metastases, death, and discontinuation of trial treatment or planned evaluations for any reason within 12 months). Proportions were compared using a 2-sided Fisher exact test. Conventional progression-free and overall survival were estimated using the Kaplan-Meier method. Adverse events were graded with Common Terminology Criteria for Adverse Events, version 4.03. All randomized patients were included in an intention-to-treat analysis.",NON-PATIENT
72,"Eyes were randomly assigned to either an argon laser trabeculoplasty (ALT)-trabeculectomy-trabeculectomy (ATT) sequence or a trabeculectomy-ALT-trabeculectomy (TAT) sequence. The second and third interventions were offered after failure of the first and second interventions, respectively.",NON-PATIENT
73,Eyes received either one drop of brimonidine 0.2% or apraclonidine 0.5% before laser surgery.,NON-PATIENT
74,"The primary outcome was mean change in visual acuity (VA) letter score (VALS) from the randomization visit to the 6-month follow-up visit, based on the best-corrected electronic Early Treatment Diabetic Retinopathy Study VALS (scores range from 0-100; higher scores indicate better VA). The noninferiority margin was 5 letters, and statistical testing for noninferiority was based on a 1-sided 97.5% confidence interval.",NON-PATIENT
75,Improvement of NSCLC symptoms (2-point or greater increase in score on the summed lung cancer subscale of the Functional Assessment of Cancer Therapy-Lung [FACT-L] instrument) and tumor regression (>50% decrease in lesion size on imaging studies).,NON-PATIENT
76,Latanoprost 0.005% given every evening and TDFC twice daily.,NON-PATIENT
77,Patients received a single dose of 5 ml of 0.5% ropivacaine during ultrasound-guided SGB before induction of general anaesthesia in the SGB group.,NON-PATIENT
78,Children aged 12 years or younger with a diagnosis of DKA. Children with septic shock and those who had received insulin before enrollment were excluded.,PATIENT
79,"Eyes were assigned randomly to sham with prompt focal/grid laser, 0.5 mg of intravitreal ranibizumab with prompt or deferred (≥24 weeks) laser, or 4 mg of intravitreal triamcinolone acetonide with prompt laser.",NON-PATIENT
80,Random assignment to 4 monthly injections of aflibercept vs vitrectomy with PRP. Both groups could receive aflibercept or vitrectomy during follow-up based on protocol-specific criteria.,NON-PATIENT
81,"Phaco-EX-PRESS P50 or Phaco-NPDS with Esnoper V2000, both groups with mitomycin C (0.2 mg/ml for 2 min).",NON-PATIENT
82,Central corneal thickness was determined with ultrasonic pachymeters of the same make and model at all clinical sites of the OHTS.,NON-PATIENT
83,"The setting for this study was a series of multicentered, private, and university-affiliated ophthalmology clinics in the United States.",NON-PATIENT
84,"A personal health record was used to store the list of patient medications and reminder preferences. On the basis of those data, participants randomized to the intervention received daily messages, either text or voice, reminding them to take their medication. Participants randomized to the control group received usual care.",NON-PATIENT
85,"Eligible patients with a baseline IOP greater than 21 mm Hg were randomized to either SLT or prostaglandin analog (PGA; travoprost, 0.004%). The SLT was repeated if the IOP reduction was less than 20.0% from baseline at the 1- or 3-month follow-up visit.",NON-PATIENT
86,Randomized clinical trial at tertiary eye care institutions of 100 patients diagnosed as having PAC or PAC glaucoma in which the angles had opened at least 180° (visible posterior trabecular meshwork on gonioscopy) after laser iridotomy. Recruitment and baseline were completed from June 2009 to April 2012 and 6-month follow-up was completed from December 2009 to November 2012.,PATIENT
87,"Eight ophthalmic practices in the USA and 1 in France, primarily associated with academic centers.",NON-PATIENT
88,"Randomized, controlled clinical trial.",NON-PATIENT
89,"Interventional case series, prospective, randomized, masked, controlled clinical trial.",NON-PATIENT
90,"This open-label, multicenter, randomized, phase 3 trial conducted in 120 centers in 21 countries enrolled 290 patients between July 25, 2016, and November 12, 2018. Eligible patients were 18 years of age or older and had advanced, recurrent, or metastatic ALK-positive NSCLC.",PATIENT
91,The primary end point was 1-year overall survival.,NON-PATIENT
92,One eye per patient with primary open-angle glaucoma and stable intraocular pressure (IOP).,PATIENT
93,A prospective randomized study.,NON-PATIENT
94,"Mean intraocular pressure (IOP), postoperative medications, visual acuity, success rate, and complications.",NON-PATIENT
95,"Participants were surveyed at baseline and at 2 weeks, 6 months, and 12 months postintervention. The outcome was 7-day point prevalent abstinence.",NON-PATIENT
96,Glaucoma progression was defined by specific visual field and optic disc outcomes. Criteria for perimetric progression were computer based and defined as the same 3 or more test point locations showing significant deterioration from baseline in glaucoma change probability maps from 3 consecutive tests. Optic disc progression was determined by masked graders using flicker chronoscopy plus side-by-side photogradings.,NON-PATIENT
97,"Randomized, controlled trial.",NON-PATIENT
98,"The Lung Cancer Master Protocol (Lung-MAP) S1400I phase 3, open-label randomized clinical trial was conducted from December 18, 2015, to April 23, 2018, randomizing patients in a 1:1 ratio to nivolumab alone or combined with ipilimumab. The median follow-up in surviving patients was 29.5 months. The trial was conducted through the National Clinical Trials Network and included patients with advanced immunotherapy-naive SqNSCLC and a Zubrod score of 0 (asymptomatic) to 1 (symptomatic but completely ambulatory) with disease progression after standard platinum-based chemotherapy. Randomization was stratified by sex and number of prior therapies (1 vs 2 or more). Data were analyzed from May 3, 2018, to February 1, 2021.",PATIENT
99,Patients were randomized to treatment with dorzolamide or placebo (the vehicle of dorzolamide).,NON-PATIENT
100,"A randomised, double-blinded, placebo-controlled study.",NON-PATIENT
101,"Graft failure, defined as a regrafting procedure or a cloudy cornea for 3 consecutive months.",NON-PATIENT
102,The PORT-C randomized clinical trial was conducted in 394 patients with pIIIA-N2 NSCLC treated with complete resection and 4 cycles of platinum-based chemotherapy between January 2009 and December 2017. Data were analyzed between March 2019 and December 2020.,PATIENT
103,40 unpremedicated outpatients with history of primary open angle glaucoma undergoing trabeculectomy.,PATIENT
104,"Surgical complications, reoperations for complications, visual acuity, and cataract progression.",NON-PATIENT
105,"Patients received BBFC (n = 193), brinzolamide 1% (n = 192), or brimonidine 0.2% (n = 175) BID.",NON-PATIENT
106,Referral centers.,NON-PATIENT
107,"One thousand seventy-seven patients, > or =30 years old, were enrolled at 18 European centers. The patients met inclusion criteria: intraocular pressure, 22 to 29 mmHg; 2 normal and reliable visual fields (VFs) (on the basis of mean deviation and corrected pattern standard deviation [PSD]); and a normal optic disc, as determined by an optic disc reading center.",PATIENT
108,"Correlation of mean central corneal thickness with race, baseline IOP, refraction, age, gender, systemic hypertension, and diabetes.",NON-PATIENT
109,Patients 18 to 85 years of age who had previous trabeculectomy and/or cataract extraction with intraocular lens implantation and uncontrolled glaucoma with intraocular pressure (IOP) ≥18 mm Hg and ≤40 mm Hg on maximum tolerated medical therapy.,PATIENT
110,Treatment with dorzolamide or placebo (the vehicle of dorzolamide) in 1 or both eyes.,NON-PATIENT
111,Surgery failure was defined as the need of an additional intraocular procedure or the need of more than one medication to achieve intraocular pressure control to the target level. Intragroup and intergroup comparisons were made with respect to filtration outcome among the SGTP and PGTP patients.,NON-PATIENT
112,"Two-hundred sixty-five eyes with PVR randomized to perfluoropropane gas and silicone oil with follow-up through 3 years (cohort 1) and 249 eyes with attached maculas at 36 months (121 eyes randomized to long-acting gas [either sulfur hexafluoride or perfluoropropane] and 128 eyes randomized to silicone oil) with follow-up up to 6 years (cohort 2). Both cohorts consisted of eyes that had and had not undergone vitrectomy for PVR (groups 1 and 2, respectively) before randomization. Of the 265 eyes in cohort 1, 24-month follow-up data were available for 218 eyes (82%) and 36-month follow-up data were available for 196 eyes (74%). Of 208 eyes in cohort 2, 48-month follow-up data were available for 146 eyes (70%), 60-month follow-up data for 119 eyes (57%), and 72-month follow-up data for 73 eyes (35%).",PATIENT
113,Three public hospitals in South Africa.,NON-PATIENT
114,"Two hundred fifty-five patients aged 50 to 80 years (median, 68 years) with early glaucoma, visual field defects (median mean deviation, -4 dB), and a median IOP of 20 mm Hg, mainly identified through a population screening. Patients with an IOP greater than 30 mm Hg or advanced visual field loss were ineligible.",PATIENT
115,People living in the community in various regions of New Zealand.,NON-PATIENT
116,"Anterior chamber cells and flare were clinically graded at the slit lamp. Anterior chamber flare was objectively assessed with the Kowa FM500 Laser Flare Meter (Kowa Co. Ltd, Tokyo, Japan) for up to 3 months after surgery. Intraocular pressure and corneal endothelial specular microscopy with morphometric cell analysis were performed for up to 1 year after surgery.",NON-PATIENT
117,"Participants were African Americans with at least 2 of the following medical conditions: high blood pressure, elevated cholesterol and/or triglycerides, heart attack, angina, stroke, irregular heartbeats, palpitations, shortness of breath, dizziness or fainting, diabetes, and tobacco use.",PATIENT
118,"The NRG-LU001 randomized clinical trial was an open-label, phase 2 study conducted from August 24, 2014, to December 15, 2016. Patients without diabetes who were diagnosed with unresectable stage III NSCLC were stratified by performance status, histology, and stage. The setting was international and multi-institutional. This study examined prespecified endpoints, and data were analyzed on an intent-to-treat basis. Data were analyzed from February 25, 2019, to March 6, 2020.",PATIENT
119,Study patients were randomized to undergo placement of a 350-mm(2) Baerveldt glaucoma implant or trabeculectomy with mitomycin C (0.4 mg/ml for 4 minutes).,NON-PATIENT
120,"This multicenter, phase 3 West Japan Thoracic Oncology Group (WJTOG) 0105 randomized clinical trial was conducted between September 2001 and September 2005 in Japan. Patients with histologically or cytologically confirmed non-small-cell lung cancer with unresectable stage III disease were assessed for eligibility. Additional data were analyzed from January 2018 to December 2019.",PATIENT
121,"Participants were randomized to receive lutein (10 mg) + zeaxanthin (2 mg), DHA (350 mg) + EPA (650 mg), lutein + zeaxanthin and DHA + EPA, or placebo. All participants were also asked to take the original AREDS formulation or accept a secondary randomization to 4 variations of the AREDS formulation, including elimination of beta carotene, lowering of zinc dose, or both.",NON-PATIENT
122,Patients undergoing trabeculectomy (with or without cataract surgery) or tube shunt surgery.,PATIENT
123,"Intraocular pressure measurements were recorded before surgery and at 1, 2, and 4 hours after surgery. The difference between the preoperative IOP (baseline) and the highest recorded postoperative IOP was recorded as the maximum IOP change. The mean of the maximum IOP change for each group was analyzed using a two-sample, one-tailed t test.",NON-PATIENT
124,"The primary end point was overall survival (OS). Secondary end points included investigator-assessed progression-free survival (IA-PFS) and response per Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, version 1.1.",NON-PATIENT
125,"Temporal clear corneal phacoemulsification and foldable IOL implantation was performed in all eyes. In the asp+IOL group, trabecular aspiration was performed with a suction force of 100 to 200 mm Hg under light tissue-instrument contact using a modified intraocular aspiration probe. A modified Cairns-type trabeculectomy without adjunctive antimetabolites was performed superiorly in the triple procedure eyes after IOL implantation.",NON-PATIENT
126,Standard care (observation or grid photocoagulation) versus 1 or 4 mg intravitreal triamcinolone.,NON-PATIENT
127,"Eighty patients with type 2 diabetes allocated to three groups: control, home training, and supervised training.",PATIENT
128,"Cost-effectiveness analysis from the hospitals' perspective within a multicentre randomised controlled trial with concealed allocation, blinded assessors and intention-to-treat analysis.",NON-PATIENT
129,"Participants were randomized in two groups (1:1 ratio) by opaque envelope method. Individualized nutrition counseling with dietary modification and routine antenatal care was provided to all. Fifty women received myoinositol 1000 mg twice daily; 50 controls did not receive myoinositol. Fasting and postprandial glucose levels were assessed after two weeks. Women not achieving glycemic targets (fasting glucose <95 and postprandial glucose <120 mg/dL) were given pharmacologic therapy. Contributory factors in women requiring additional pharmacologic therapy, maternal and fetal outcomes were noted.",NON-PATIENT
130,Multicenter randomized clinical trial.,NON-PATIENT
131,We continued to administer maximum-tolerated medical therapy for glaucoma. Patients took the study medication every eight hours. Study medications were either apraclonidine hydrochloride 0.5% or placebo (apraclonidine's vehicle).,NON-PATIENT
132,"Trial delivering counseling services by self-help booklet, telephone quit lines, or online expert system in the 48 continental United States.",NON-PATIENT
133,"This post hoc analysis evaluates data from a randomized clinical trial conducted at 55 US sites among 305 adults with proliferative diabetic retinopathy enrolled between February and December 2012. Both eyes were enrolled for 89 participants (1 eye to each study group), with a total of 394 study eyes. The final 2-year visit was completed in January 2015. Data were analyzed from April 2019 to July 2021.",PATIENT
134,"Peri-ALT IOPs and incidences of post-ALT IOP spikes at 5 minutes, 1 hour, and 24 hours were compared between the two groups.",NON-PATIENT
135,"After a washout period, the patients were randomized to a 2-week treatment period with either placebo in the morning and 0.005% latanoprost in the evening or 0.5% timolol twice daily.",NON-PATIENT
136,Seventeen clinical centers.,NON-PATIENT
137,Safety data were collected and the results for systemic safety are reported in this paper.,NON-PATIENT
138,"The study was designed as a randomized, 6-month double-masked parallel group, multicenter study comparing latanoprost with timolol followed by an 18-month open-label, multicenter study in which all patients were treated with latanoprost.",NON-PATIENT
139,Randomised controlled trial.,NON-PATIENT
140,A total of 79 eyes of 79 primary open-angle glaucoma (POAG) patients in need of combined surgery were randomized to a silicone IOL group (36 eyes) and acrylic IOL group (43 eyes).,PATIENT
141,Nonperfused group: random assignment to panretinal photocoagulation or watchful waiting. Macular edema group: random assignment to grid pattern photocoagulation or watchful waiting. Natural history groups: no intervention.,NON-PATIENT
142,Six IOP parameters were evaluated and correlated to visual field outcome. The subgroups with the two types of glaucoma (capsular and simple) were analyzed separately.,NON-PATIENT
143,Vision-specific QoL using the NEI VFQ-25 and estimation of minimally important differences (MID) were the main outcome measures. Cross-sectional distribution- and anchor-based approaches were used to estimate MID. Clinical anchor measures included the mean deviation (MD) and logMAR visual acuity (VA) measurements. Clinically significant changes in anchor were defined as ≥2 dB MD and ≥0.2 logMAR.,NON-PATIENT
144,Intraocular pressure (IOP) and requirement for topical glaucoma drugs.,NON-PATIENT
145,"Primary outcomes were a composite end point of first major cardiovascular event (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and total invasive cancer.",NON-PATIENT
146,Brimonidine tartrate 0.2% or timolol maleate 0.5% was administered twice daily.,NON-PATIENT
147,Patients at a tertiary care teaching hospital undergoing throracotomy for lung cancer.,PATIENT
148,"A randomized clinical trial enrolled 613 participants from a National Cancer Institute-designated cancer center between 2015 and 2019. Patients were 65 years and older with a solid malignant neoplasm, were starting a new chemotherapy regimen, and completed a geriatric assessment. Patients were followed up until chemotherapy completion or 6 months after initiation, whichever occurred first. Data analysis was done by intention-to-treat principle.",PATIENT
149,"Parallel, randomized, double-masked, and active-controlled study.",NON-PATIENT
150,Teaching hospital.,NON-PATIENT
151,"Astigmatism and high astigmatism at each visit. Astigmatism was classified as with-the-rule (WTR; 75 degrees -105 degrees ), against-the-rule (ATR; 0 degrees -15 degrees and 165 degrees -180 degrees ), or oblique (OBL; 16 degrees -74 degrees and 106 degrees -164 degrees ).",NON-PATIENT
152,"The controls underwent conventional SLT with 100 spots delivered using a gonioscopy lens for 360 degrees of the trabecular meshwork. The study group underwent irradiation using the same parameters with the laser applications administered on the perilimbal sclera. Study visits: 1 hour, 1, 7, 30, 60, 180, and 365 days postprocedure.",NON-PATIENT
153,Tube shunt (350-mm(2) Baerveldt glaucoma implant) or trabeculectomy with mitomycin C ([MMC]; 0.4 mg/mL for 4 minutes).,NON-PATIENT
154,A total of 607 patients with open-angle glaucoma were enrolled.,PATIENT
155,The WBRT schedule was 30 Gy in 10 fractions over 2 to 2.5 weeks. The mean SRS dose was 21.9 Gy in SRS alone and 16.6 Gy in WBRT + SRS.,NON-PATIENT
156,The contrast sensitivity and best-corrected logarithm of the minimum angle of resolution (logMAR).,NON-PATIENT
157,Setting: This pilot randomized open label trial was conducted in a single antenatal clinic in India.,NON-PATIENT
158,One thousand three hundred one OHTS subjects with central corneal thickness measurements.,PATIENT
159,350 mm(2) Baerveldt glaucoma implant or trabeculectomy with mitomycin C (MMC).,NON-PATIENT
160,"Incidence of posterior capsular opacification (PCO), best-corrected visual acuity (BCVA), intraocular pressure (IOP), number of pressure-lowering medications, and filtration success rates, defined as maintenance of target IOP while on one (criteria 1) or zero (criteria 2) pressure-lowering medications without further surgical intervention.",NON-PATIENT
161,"Randomized, controlled clinical trial.",NON-PATIENT
162,"Setting: Meir Medical Center, Kfar-Saba, Israel.",NON-PATIENT
163,"A 3-month, parallel, randomized, double-masked, active-controlled, multicenter clinical trial.",NON-PATIENT
164,"All patients received docetaxel 75 mg/m2 on day 1 and were randomly assigned to 1 of 3 doses of plinabulin (5, 10, or 20 mg/m2) on day 1 or to pegfilgrastim 6 mg on day 2. Patients were treated every 21 days for 4 chemotherapy cycles.",NON-PATIENT
165,Patients were randomly assigned to receive either lung-protective ventilation (LPV group) [tidal volume 6 ml/ kg predicated body weight (PBW) + PEEP 7 cmH,NON-PATIENT
166,"Comprehensive vision and eye examinations conducted by an optometrist. Three hundred subjects were seen by the study optometrist, with 146 judged to need treatment for a vision or eye problem. The optometrist arranged new glasses for 92 subjects; 24 were referred for a home visit by an occupational therapist; 17 were referred for glaucoma management; and 15 were referred for cataract surgery.",NON-PATIENT
167,17 Clinical Centers.,NON-PATIENT
168,"After completing a washout of ocular hypotensive medications, patients were randomized to receive either the dorzolamide-timolol combination twice daily plus placebo once daily, 0.5% timolol twice daily plus placebo once daily, or 2.0% dorzolamide three times daily.",NON-PATIENT
169,"Prospective, randomized.",NON-PATIENT
170,"Outcome measures include retention, attendance, systolic and diastolic blood pressures, weight, body mass index, hip measurement, and waist measurement as well as the Short Form-12 (SH-12) Health Survey.",NON-PATIENT
171,"Between 2005 and 2009, a total of 670 patients with non-small cell lung cancer (NSCLC) were randomised across 78 hospital sites (centres) in the UK.",NON-PATIENT
172,"Patients were randomly allocated to one of two groups. Patients in group 1 were treated with latanoprost, lubricant, and brimonidine for 4 weeks each, whereas patients in group 2 were treated with brimonidine, lubricant, and latanoprost for 4 weeks each.",NON-PATIENT
173,"Single-masked, parallel-group, prospective, randomized 24-month trial, with 90% power to detect a clinically important difference between groups.",NON-PATIENT
174,"The primary efficacy measure was unmedicated IOP ≤21 mmHg at 1 year. A secondary measure was unmedicated IOP reduction ≥20% at 1 year. Safety measures included best-corrected visual acuity (BCVA), slit-lamp observations, complications, and adverse events.",NON-PATIENT
175,Sixty-six academic and private practice study sites throughout the United States.,NON-PATIENT
176,"The primary end point was overall survival (OS), and the secondary end points included brain tumor recurrence (BTR), salvage treatment, and radiation toxic effects.",NON-PATIENT
177,"At 36 months, data were available for 81 participants with CRVO and 128 with BRVO.",PATIENT
178,Patients randomized to initial medication received a stepped medical regimen (n = 307). Those randomized to initial surgery underwent a trabeculectomy (n = 300). The baseline interview was conducted before treatment initiation. All baseline and posttreatment QOL assessments were conducted by telephone from a centralized interviewing center.,NON-PATIENT
179,"Participants were divided randomly into 2 groups with 30 participants each, the intervention and control groups. The intervention group practiced DBE for 5 minutes every day; the control group did not. Diet therapy has been recommended to both groups by their obstetrician.",NON-PATIENT
180,Intraocular pressures 1 and 3 hours after laser therapy were recorded.,NON-PATIENT
181,"Community in Sydney, Australia.",NON-PATIENT
182,Multicenter randomized clinical trial.,NON-PATIENT
183,Multinational study at 34 international sites.,NON-PATIENT
184,"Two percent dorzolamide three times a day, 0.5% timolol (Timoptic, Merck, Whitehouse Station, NJ) twice daily, and 0.5% betaxolol solution (Betoptic, Alcon, Fort Worth, Tex) twice daily.",NON-PATIENT
185,Settings: Six clinical centres.,NON-PATIENT
186,Two hundred twelve patients aged 18 to 85 years who had undergone previous trabeculectomy and/or cataract extraction with intraocular lens implantation and uncontrolled glaucoma with intraocular pressure > or =18 mm Hg and < or =40 mm Hg on maximum tolerated medical therapy.,PATIENT
187,Follow-up at 1 month postoperatively.,NON-PATIENT
188,"Progression in visual field loss constitutes the study's primary outcome variable. Secondary outcomes include health-related quality of life, visual acuity, and intraocular pressure.",NON-PATIENT
189,Two hundred twenty-eight eyes of 228 patients with primary open-angle glaucoma undergoing ALT were studied.,PATIENT
190,Subjects were randomized to undergo laser peripheral iridotomy (LPI) in one eye. Ultrasound biomicroscopy was performed before and a week after LPI.,NON-PATIENT
191,A total of 660 adults with a clinical diagnosis of open-angle glaucoma or ocular hypertension from a referred sample were enrolled. Thirty-four patients discontinued participation due to treatment-related nonserious adverse events.,PATIENT
192,Fifty consecutive patients (50 eyes) with primary open-angle or pseudoexfoliative glaucoma.,PATIENT
193,"Mean IOP at the 3-month visit at all time points (8 AM, 10 AM, 3 PM, and 5 PM).",NON-PATIENT
194,3 annual rounds of LDCT screening.,NON-PATIENT
195,"The intervention was a 10-week smoking cessation program that included a strong physician message and 12 group sessions using behavior modification and nicotine gum, plus either ipratropium or a placebo inhaler.",NON-PATIENT
196,Patients were randomized to receive either brimonidine 0.2% or apraclonidine 1.0% before and after 360 degrees ALT. Both patient and physician were masked as to which agent each patient received.,NON-PATIENT
197,"In total, 277 patients were treated with latanoprost for up to 24 months.",PATIENT
198,Adjusted mean IOP reduction at predose from baseline to week 8.,NON-PATIENT
199,"One hundred fifty-seven patients with established PVR (grade C, anterior or posterior) undergoing vitrectomy surgery.",PATIENT
200,"Randomized, controlled trial of low-dose CT versus chest radiography. (ClinicalTrials.gov registration number: NCT00006382)",NON-PATIENT
201,"Demographics, smoking and medical history, screening examination adherence and results, diagnostic follow-up procedures and complications, lung cancer diagnoses, treatment, survival, and mortality.",NON-PATIENT
202,Seventeen clinical centers.,NON-PATIENT
203,"Randomized, double-blinded, placebo-controlled study.",NON-PATIENT
204,"Encapsulated blebs developed in 25 (8.9%) of 282 eyes and were randomized to either needling (n = 14) or medical treatment with aqueous humor suppressants (n = 11). If one treatment failed to maintain intraocular pressures (IOPs) below 20 mmHg, the other treatment was initiated. If both methods failed, surgical revision or further glaucoma surgery was performed. Complete success was defined as IOP less than 20 mmHg after one treatment method. Qualified success was defined when IOPs less than 20 mmHg were obtained with both treatment methods, whereas failure was defined when IOP greater than 20 mmHg or when further surgery was indicated.",NON-PATIENT
205,Proportion of patients with SARS-CoV-2 RNA negative before day-21 and change in inflammatory markers.,NON-PATIENT
206,"Random assignment to low-dose CT or chest radiography with baseline and 1 repeated annual screening; 1-year follow-up after the final screening. Randomization was centralized and stratified by age, sex, and study center.",NON-PATIENT
207,"The interventions were carried out in the Oberstaufen health resort in Bavaria, Germany.",NON-PATIENT
208,"Randomized, masked, and partially controlled trial.",NON-PATIENT
209,"Mean diurnal IOP averaged over 8 AM, 10 AM, 3 PM, and 5 PM time points at week 6. Superiority of BBFC+TRAV over vehicle+TRAV was based on statistical significance of a treatment difference favoring BBFC+TRAV.",NON-PATIENT
210,University teaching hospital.,NON-PATIENT
211,Eight hundred fifty-four of 1077 ocular hypertensive participants within the EGPS were investigated. Four hundred twenty-nine patients were treated with dorzolamide and 425 patients received placebo.,PATIENT
212,One hundred seventy-four eyes of 174 nonselected patients with primary open-angle glaucoma (POAG) were randomized to either no adjunctive mitomycin C (MMC) control group of 93 eyes of 93 patients) or adjunctive subconjunctival MMC (MMC group of 81 eyes of 81 patients) during the primary glaucoma triple procedure (PGTP).,PATIENT
213,Falls and fractures during 12 months of follow-up were ascertained according to self-report using a monthly postcard system.,NON-PATIENT
214,"Multicenter, 3-month, randomized, double-masked, interventional comparison trial.",NON-PATIENT
215,"Prostate cancer and prespecified secondary outcomes, including lung, colorectal, and overall primary cancer.",NON-PATIENT
216,Multicenter randomized clinical trial.,NON-PATIENT
217,Participants randomly allocated (1:1) to short-term integrated rehabilitation and standard care or standard care alone over 30 days.,NON-PATIENT
218,"Adult women with type 2 diabetes and mild-to-moderate diabetic peripheral neuropathy. Out of 410 patients, 120 diabetic patients were recruited and randomly assigned to trial group (",PATIENT
219,Sixty eyes of 60 patients with refractory glaucoma were randomized to receive intraoperative MMC (0.5 mg/ml for 5 minutes) (n = 34) or balanced salt solution (n = 26) during Ahmed Glaucoma Valve implantation.,NON-PATIENT
220,"Sorafenib 400mg twice daily plus subcutaneous IFN, 9 million units (MU) three times a week (Arm A) or 3 MU five times a week (Arm B).",NON-PATIENT
221,"Randomized, single-blind controlled trial.",NON-PATIENT
222,Visual acuity area under the curve (adjusted for baseline VA) and clearance of vitreous hemorrhage.,NON-PATIENT
223,"One hundred women with singleton pregnancy and gestational diabetes diagnosed between 14-28 weeks' gestation were included. Overt diabetes, twin pregnancy, pre-existing renal disease, heart disease and other chronic medical disorders were exclusions.",PATIENT
224,"Patients were randomly assigned to receive either a high (600 IU/kg, n = 32) or a low (300 IU/kg, n = 31) initial dose of heparin. Target levels of activated clotting time during CPB were >600 seconds in the high heparin dose group and >400 seconds in the low heparin dose group.",NON-PATIENT
225,"Low-pressure glaucoma patients 30 years of age or older were identified. Exclusion criteria included an untreated pressure of more than 21 mmHg, advanced visual field loss, and contraindications to study medications.",PATIENT
226,Prospective randomized clinical trial.,NON-PATIENT
227,"The study eyes underwent primary trabeculectomy, phacoemulsification, and posterior chamber IOL implantation. Adjunctive mitomycin C was used selectively, primarily in patients with one or more risk factors for filtration failure.",NON-PATIENT
228,"The incidences of YAG capsulotomy for PCO were compared between the control and MMC groups and also between the control group and the MMC subgroups (1 minute, 3 minutes, and 5 minutes of MMC application) using Kaplan-Meier analysis with Mantel-Cox log-rank test. Cox proportional hazard regression analysis also was performed to identify significant factors affecting capsular opacification.",NON-PATIENT
229,"The short-term IOP reduction of latanoprost and timolol in patients with CACG. IOP was measured at baseline, and after 2, 7, and 14 days of treatment. In addition, the short-term ocular and systemic adverse events of the two drugs were evaluated.",NON-PATIENT
230,Three tertiary-referral teaching hospital vitreoretinal surgical units.,NON-PATIENT
231,Prospective double-masked randomized crossover study.,NON-PATIENT
232,"Preoperative and postoperative intraocular pressure (IOP) values, visual acuity, the need for antiglaucoma medication, previous surgical procedures, and the need for further surgical interventions were monitored.",NON-PATIENT
233,A randomized controlled trial.,NON-PATIENT
234,"Participants were randomised to receive daily 60 000 IU of cholecalciferol (oral nano-liquid droplets) for 7 days with therapeutic target 25(OH)D>50 ng/ml (intervention group) or placebo (control group). Patients requiring invasive ventilation or with significant comorbidities were excluded. 25(OH)D levels were assessed at day 7, and cholecalciferol supplementation was continued for those with 25(OH)D <50 ng/ml in the intervention arm. SARS-CoV-2 RNA and inflammatory markers fibrinogen, D-dimer, procalcitonin and (CRP), ferritin were measured periodically.",NON-PATIENT
235,"Eyes were randomized to receive laser photocoagulation at high-risk prethreshold ROP (early treated [ET]) or to be conventionally managed (CM), receiving treatment only if threshold ROP developed.",NON-PATIENT
236,People with diagnosed or suspected non-small cell lung cancer and moderate-to-high risk of postoperative complications.,PATIENT
237,Improvement of best-corrected logarithm of the minimum angle of resolution visual acuity (VA) by > or =5 letters after 2 years and incidence of moderate or severe adverse events.,NON-PATIENT
238,"A prospective 90 day, multi-centered, placebo-controlled, doublemasked parallel study.",NON-PATIENT
239,"A prospective, multicenter, interventional cohort from the prerandomization phase of a randomized clinical trial evaluating use of a supraciliary implant for treatment of IOP was conducted at multiple ophthalmology clinics. A total of 609 patients (609 eyes) with primary open-angle glaucoma and cataract were included.",PATIENT
240,"A long lapse in care of 8 or more weeks past a scheduled examination, dropout from follow-up, visual acuity at 5 years.",NON-PATIENT
241,"This was a randomized, multicenter, investigator-masked, prospective, parallel-group, clinical trial.",NON-PATIENT
242,"The IOP reductions in the ripasudil and placebo groups were analyzed with a repeated-measures analysis of variance model at weeks 4, 6, and 8, at trough (before instillation [9 am]) and peak (2 hours after instillation [11 am]) levels.",NON-PATIENT
243,One hundred fifty-one patients with their first head and neck squamous cell carcinoma treated with high expectation for cure and living close by. They were randomized into 3 arms to receive 3 years of treatment.,PATIENT
244,"Oral selenium (200 microg/d from L-selenomethionine) and matched vitamin E placebo, vitamin E (400 IU/d of all rac-alpha-tocopheryl acetate) and matched selenium placebo, selenium + vitamin E, or placebo + placebo for a planned follow-up of minimum of 7 years and a maximum of 12 years.",NON-PATIENT
245,"The experimental group received an information booklet and a 30-minute face-to-face session, involving respiratory education and breathing exercise training, with a physiotherapist. The control group received the information booklet only.",NON-PATIENT
246,Patients 18 to 85 years of age who had previous trabeculectomy and/or cataract extraction with intraocular lens implantation and uncontrolled glaucoma with intraocular pressure (IOP) > or =18 mm Hg and < or =40 mm Hg on maximum tolerated medical therapy.,PATIENT
247,"After a 3-week run-in of timolol (TIMOPTIC; Merck & Co., Inc., Whitehouse Station, NJ) twice daily, eligible patients received either the combination (COSOPT; Merck & Co., Inc., Whitehouse Station, NJ) twice daily (plus placebo to ensure masking), timolol twice daily (plus placebo to ensure masking), or dorzolamide (TRUSOPT; Merck & Co. Inc., Whitehouse Station, NJ) three times daily for 3 months.",NON-PATIENT
248,"Quality of life, patients' satisfaction, general practitioners' satisfaction, survival, symptom-free survival, progression-free survival, use of resources, and comparison of costs.",NON-PATIENT
249,Feasibility study for the ongoing National Lung Screening Trial.,NON-PATIENT
250,Prospective randomized clinical trial.,NON-PATIENT
251,A baseline VF was created using the average of 2 reliable Humphrey full-threshold examinations. A baseline diurnal IOP curve was performed without IOP-lowering medication.,NON-PATIENT
252,"Seven hundred and twenty-five patients with CVO (728 eyes) divided into 4 study groups on the basis of the perfusion status of the retina and presence of decreased vision associated with macular edema: perfused, nonperfused, indeterminate, and macular edema.",PATIENT
253,"Subjects were randomly assigned to treatment with latanoprost 0.005% (n = 127), fixed-combination latanoprost 0.005%-timolol 0.5% (FC, n = 116), or timolol 0.5% (n = 126) one drop, once daily in the morning for 1 year. All subjects were treated in both eyes. Specular microscopy and ultrasonic pachymetry were performed before treatment, and after 6 and 12 months of treatment.",NON-PATIENT
254,"The SCORE2 randomized noninferiority clinical trial was conducted at 66 private practice or academic centers in the United States, and included 362 patients with macular edema due to central retinal or hemiretinal vein occlusion who were randomized 1:1 to receive aflibercept or bevacizumab. The first participant was randomized on September 17, 2014, and the last month 6 visit occurred on May 6, 2016. Analyses included data available as of December 30, 2016.",PATIENT
255,Thirty-nine patients (78 eyes) with bilateral primary open angle glaucoma were included in the study.,PATIENT
256,Masked BBFC or vehicle (3 times daily) adjunctive to TRAV for 6 weeks.,NON-PATIENT
257,"A 3-month, parallel, randomized, double-masked, active-controlled, multicenter clinical trial.",NON-PATIENT
258,"Diurnal curves of intraocular pressure (IOP) were performed on the baseline day and after 0.5, 3, 6, and 12 months of treatment. The IOP measurements were performed at 8:00 AM, 12:00 noon, 4:00 PM, and 8:00 PM. Outflow facility (""C"") was measured on the baseline day and on the last day of the study with a Schiotz electronic tonometer. A two-tailed Student's t test for paired or unpaired data was used for statistical evaluation of differences between treatment and baseline values or between the latanoprost and timolol group. Diurnal IOP measurements were compared hour by hour. Mean values of the two eyes IOP and ""C"" were used for analysis.",NON-PATIENT
259,Fifteen supervised prehabilitation sessions delivered with either a dense regimen of five sessions/week for 3 weeks (experimental group) or a non-dense regimen of three sessions/week for 5 weeks (control group).,NON-PATIENT
260,"Intraocular pressure (IOP), pulse rate, and blood pressure were measured at 8 am, 12 noon, and 4 pm after each 4-week treatment. Ocular perfusion pressure (OPP) was calculated.",NON-PATIENT
261,"Six counselor-initiated counseling calls using motivational interviewing techniques and focusing on teaching adaptive coping skills based on the transactional model of stress and coping along with tailored self-directed materials (including nicotine patches, if not contraindicated) (n  =  245) vs. tailored self-directed materials (including nicotine patches, if not contraindicated) (n  =  251).",NON-PATIENT
262,"Maximum inspiratory pressure (PImax), maximum expiratory pressure (PEmax) lung expansion volume, and 6-min walking test (6MWT) were performed on the day of chest tube removal (baseline), and 2, 6, and 12 weeks postoperatively.",NON-PATIENT
263,Automated perimetry and a daytime IOP curve were taken every second month during the 2-year follow-up.,NON-PATIENT
264,Current smokers who are family members and close friends of patients with lung cancer.,PATIENT
265,A teaching hospital.,NON-PATIENT
266,The primary outcome was the change in cardiorespiratory fitness measured by the V̇O,NON-PATIENT
267,"Two head and neck multidisciplinary cancer clinics in university teaching hospitals taking cases from 4 to 5 million people in Queensland, Australia, combined to enter appropriate patients into this trial.",NON-PATIENT
268,"Randomized, prospective study.",NON-PATIENT
269,Nurse led follow up of outpatients compared with conventional medical follow up.,NON-PATIENT
270,"Randomized, double-masked, controlled clinical trial.",NON-PATIENT
271,"In Study 1, 237 patients applied OPC-1085EL (n = 118) or latanoprost (n = 119) for 8 weeks. In Study 2, 193 patients applied OPC-1085EL (n = 78), carteolol (n = 78), or carteolol/latanoprost concomitant therapy (n = 37) for 8 weeks.",NON-PATIENT
272,"Temporal clear corneal phacoemulsification and foldable IOL implantation was performed in all eyes. In the phaco-aspiration group, trabecular aspiration was performed with a suction force of 100-200 mmHg under light tissue-instrument contact using a modified intraocular aspiration probe. A modified Cairns-type trabeculectomy without adjunctive antimetabolites was performed superiorly in the phaco-trab eyes after IOL implantation.",NON-PATIENT
273,"An open-label, randomized, controlled, parallel-group study.",NON-PATIENT
274,"The primary endpoint was improvement in progression-free survival (PFS) with So-Su versus Su-So, assessed from randomisation to progression or death during second-line therapy. Secondary endpoints included overall survival (OS) and safety.",NON-PATIENT
275,"Chemotherapy-related morbidity of six common chemotherapy-related symptoms (nausea, vomiting, fatigue, mucositis, hand-foot syndrome and diarrhoea).",NON-PATIENT
276,"Lung-RADS classifications for LDCT screenings. Lung-RADS categories 1 to 2 constitute negative screening results, and categories 3 to 4 constitute positive results.",NON-PATIENT
277,"The Physicians' Health Study II is a randomized, double-blind, placebo-controlled factorial trial of vitamins E and C that began in 1997 and continued until its scheduled completion on August 31, 2007. A total of 14,641 male physicians in the United States initially aged 50 years or older, including 1307 men with a history of prior cancer at randomization, were enrolled.",PATIENT
278,University-affiliated teaching hospital and laboratory.,NON-PATIENT
279,"The multicentre, randomised, open-label, phase 3 SWITCH study assessed So-Su versus Su-So in patients with mRCC without prior systemic therapy, and stratified by Memorial Sloan Kettering Cancer Center risk score (favourable or intermediate).",PATIENT
280,Patients randomized to initial medications (n=307) received a stepped regimen of medications to lower intraocular pressure. Those randomized to initial surgery (n=300) underwent trabeculectomy to lower intraocular pressure.,NON-PATIENT
281,Fifty-five patients scheduled for glaucoma surgery.,PATIENT
282,Patients were randomly assigned no antibiotics or a 5-day course of intravenous amoxicillin-clavulanic acid postoperatively.,NON-PATIENT
283,We enrolled 174 glaucoma patients with inadequate IOP control on maximally tolerated medical therapy. All were candidates for either laser trabeculoplasty or invasive surgical intervention. We enrolled only one eye per patient.,PATIENT
284,"Randomized, double-masked, multicenter, placebo-controlled trial.",NON-PATIENT
285,Randomized controlled trial.,NON-PATIENT
286,"Changes in visual acuity, recurrent retinal detachment, and incidence of complications.",NON-PATIENT
287,"In the operating room, an infusion of 5% dextrose into a peripheral vein was started. The propofol group (n = 20) received 0.5 mg/kg i.v. propofol bolus followed immediately by a continuous 0.5 mg/kg/hr infusion. The control group (n = 20) received only the dextrose solution. A peribulbar block was performed with bupivacaine with added adrenaline, plus lidocaine. The ocular pressure (tonometer) on the eye undergoing trabeculectomy and the other eye, blood pressure (BP), and heart rate (HR) were measured at the following times: (1) preoperatively; (2) 2 minutes; (3) 5 minutes; (4) 10 minutes; (5) 15 minutes after propofol bolus administration for the propofol group (approximately 4 minutes after the peribulbar blockade on the eye undergoing surgery for the propofol and control groups).",NON-PATIENT
288,University hospital.,NON-PATIENT
289,Intraocular pressure (IOP) and side effects.,NON-PATIENT
290,19 612 participants aged 55 to 64 years (under-65 cohort) and 7110 participants aged 65 to 74 years (65+ cohort) at randomization.,PATIENT
291,"Late postoperative complications (beyond 3 months), reoperations for complications, and decreased vision from complications.",NON-PATIENT
292,"A double-masked, parallel-group, active-controlled, multicenter clinical trial of 12 months' duration.",NON-PATIENT
293,Mean percent change in central endothelial cell density and central corneal thickness after 1 year of treatment.,NON-PATIENT
294,Teaching hospital.,NON-PATIENT
295,A dose of 100 mg of aspirin (n=19 934) or aspirin placebo (n=19 942) administered every other day.,NON-PATIENT
296,"Study eyes were assigned randomly to adjunctive treatment with thrice-daily brimonidine tartrate 0.15% (n = 41), dorzolamide hydrochloride 2% (n = 40), or brinzolamide 1% (n = 39) for 4 months.",NON-PATIENT
297,"Low-pressure glaucoma (LPG) patients 30 years or older were identified. Exclusion criteria included an untreated pressure > 21 mmHg, advanced VF loss, and contraindications to study medications.",PATIENT
298,"Participants were individually randomized (1-1 ratio) to either be exempted from the standard $5 charge per prescription item for one year (2019-2020) (n = 591) or usual care (n = 469). Those in the intervention group did not pay the standard NZ$5 charge, and pharmacies billed the study for these. Participants continued to pay any other costs for prescription medicines. Those in the control group continued to pay all prescription charges for the year although they may have received one-off assistance from other agencies.",NON-PATIENT
299,Eyes were randomly assigned to receive deep sclerectomy in one eye and trabeculectomy in the other eye.,NON-PATIENT
300,Multicenter randomized clinical trial.,NON-PATIENT
301,"Six-month, phase 3, randomized, multicenter, double-masked clinical trial.",NON-PATIENT
302,"The primary outcome was length of stay (hospital bed-days). Secondary outcomes presented in this paper included: all-cause hospitalisations, hospitalisations for diabetes/mental health problems/COPD, deaths, and emergency department visits.",NON-PATIENT
303,"Double-blind, randomized phase 2 trial conducted from November 2000 to April 2001 in 30 US academic and community oncology centers. Patients (N = 221) had either stage IIIB or IV NSCLC for which they had received at least 2 chemotherapy regimens.",PATIENT
304,"The primary outcome measure, circadian IOP, was measured at eight time points over the course of 24 hours beginning at 8 am on day 28 and with the last measurement at 8 am on day 29. IOP was also measured at 8 am and 10 am at baseline and at 8 am on day 14. Safety measures included adverse events, biomicroscopy, visual acuity, heart rate, and blood pressure.",NON-PATIENT
305,Sixteen patients with ocular hypertension or with primary open-angle glaucoma were studied.,PATIENT
306,"Subjects in these subsample groups have reported complaints of glare and wanted to administer eye drops to get quick eye relief and quality of vision for their daily activities including driving and computer works. Following 9 months of treatment with NAC lubricant eye drops, most patients' glare scores were improved or returned to normal in disability glare tests with Halometer DG. Improvement in disability glare was accompanied with independent improvement in acuity. Furthermore, patients with the poorest pretreatment vision were as likely to regain certain better visual function after 9 months of treatment with N-acetylcarnosine lubricant eye drops as those with the worth pretreatment vision.",NON-PATIENT
307,Trabeculectomy with 1000 cGy beta radiation or standard trabeculectomy without beta radiation (placebo).,NON-PATIENT
308,"The primary outcome measure described in this paper was QOL. The QOL instrument is multidimensional and incorporates both disease-specific and generic measures, including the Visual Activities Questionnaire, Sickness Impact Profile, and a Symptom and Health Problem CHECKLIST:",NON-PATIENT
309,"Secondary analysis of a randomized clinical trial that included 312 participants with macular edema secondary to CRVO or hemiretinal vein occlusion (HRVO) who were not taking IOP-lowering medications at baseline. First randomization occurred on September 14, 2014, and contained data through data freeze on April 1, 2020. Analysis took place from April 2020 through December 2020.",PATIENT
310,"IOP was measured at 10:00 AM and at 5:00 PM at baseline and at week 8, and before 12:00 noon at week 2. Ocular and systemic safety assessments were performed.",NON-PATIENT
311,Participants were 60 pregnant women who suffered from GDM and who attended the antenatal polyclinic at the hospital between June 2015 and June 2016.,PATIENT
312,"A double-masked, randomized, parallel comparison.",NON-PATIENT
313,Eyes were randomized to receive laser photocoagulation at high-risk prethreshold ROP or to receive treatment only if threshold ROP developed.,NON-PATIENT
314,"Patients 18 to 85 years of age who had previous trabeculectomy, cataract extraction with intraocular lens implantation, or both and uncontrolled glaucoma with intraocular pressure (IOP) > or =18 mm Hg and < or =40 mm Hg on maximum tolerated medical therapy.",PATIENT
315,"The primary outcome was the proportion of patients who experienced a failure event (ie, locoregional disease progression, distant metastases, death, and discontinuation of trial treatment or planned evaluations for any reason within 12 months). Proportions were compared using a 2-sided Fisher exact test. Conventional progression-free and overall survival were estimated using the Kaplan-Meier method. Adverse events were graded with Common Terminology Criteria for Adverse Events, version 4.03. All randomized patients were included in an intention-to-treat analysis.",NON-PATIENT
316,Subjects over the age of 50 years diagnosed as PACSs.,PATIENT
317,"One hundred twenty eyes of 120 patients with open-angle glaucoma or ocular hypertension who had inadequate IOP control after at least 6 weeks of monotherapy with a once-daily PGA (bimatoprost, latanoprost, or travoprost).",PATIENT
318,"Ninety-six patients were identified from the authors' tertiary glaucoma practice who were treated with brimonidine. Their glaucoma was uncontrolled despite maximal tolerated medical therapy before receiving brimonidine, and some had previously undergone argon laser trabeculoplasty or filtration surgery. The patients were subdivided according to their glaucoma diagnosis: open-angle (OAG), angle-closure (ACG), mixed mechanism, and congenital glaucoma. Both the short- (about 2 weeks) and long-term results were evaluated. Twenty-two patients were excluded because additional medication changes were made at the time of introduction of brimonidine.",PATIENT
319,"Sixty-six patients underwent either laser peripheral iridotomy, argon laser trabeculoplasty, or neodymium:yttrium-aluminum-garnet laser capsulotomy.",PATIENT
320,Identification of complications and IOP.,NON-PATIENT
321,"The primary outcome was change in hemoglobin A1c at 6 months post intervention. Secondary outcomes included body weight, body mass index, blood pressure, levels of cholesterol and triglycerides, well-being (WHO-5), and general health status (EQ-5D and SF-36).",NON-PATIENT
322,Progression of visual field loss.,NON-PATIENT
323,"A prospective, randomized study.",NON-PATIENT
324,No vision assessment or intervention,NON-PATIENT
325,"Distance and near visual acuity (logMAR) and composite scores on the 25-item version of the National Eye Institute Visual Function Questionnaire, both assessed at a 12-month follow-up home visit.",NON-PATIENT
326,"The acute PACG eye of each consenting patient received topical pilocarpine (4%) and topical timolol (0.5%). The patients were then randomized into one of two treatment groups. The ALPI group received immediate ALPI under topical anesthesia. The medical treatment group was given 500 mg of intravenous acetazolamide, followed by oral acetazolamide 250 mg four times daily, and an oral potassium supplement until IOP levels normalized. Intravenous mannitol also was administered to the latter group if the presenting IOP was higher than 60 mmHg. The acute PACG eye of both groups continued to receive topical pilocarpine (1%) until peripheral iridotomy could be performed.",NON-PATIENT
327,Fifty medically uncontrolled CACG eyes without cataract of 50 patients.,PATIENT
328,Randomised controlled double-blind study.,NON-PATIENT
329,"The outcome measures were the levels of fasting blood glucose (FBG), and vital measurements were taken from both groups for 30 days. Data analysis was done using SPSS statistical software. Results • The experimental group showed significant decreases in respiratory rate and levels of FBG when compared with the control group. The intervention group's results for pulse rate and systolic and diastolic blood pressure were within normal limits, and no measurable differences existed between the two groups for those measures.",NON-PATIENT
330,"The EMGT progression is defined by sustained increases of visual field loss in three consecutive C30-2 Humphrey tests, as determined from computer-based analyses, or by optic disc changes, as determined from flicker chronoscopy and side-by-side comparisons of fundus photographs performed by masked, independent graders.",NON-PATIENT
331,"Primary outcome measure was surgical failure within 12 months (intraocular pressure > 21 mm Hg while receiving no treatment for ocular hypotension). Secondary outcomes were visual acuity, surgical reintervention for cataract, and intraoperative and postoperative complications.",NON-PATIENT
332,"A multicenter phase 2 randomized clinical trial, the Arginine Deiminase and Mesothelioma (ADAM) study, was conducted between March 2, 2011, and May 21, 2013, at 8 academic cancer centers. Immunohistochemical screening of 201 patients (2011-2013) identified 68 with advanced ASS1-deficient malignant pleural mesothelioma.",PATIENT
333,616 men and women aged 70 years and over (mean age 81 years) recruited mainly from people attending outpatient aged care services.,PATIENT
334,The Infant Aphakia Treatment Study is a randomized clinical trial with 5 years of follow-up that involved 114 infants with unilateral congenital cataracts at 12 sites. A traveling examiner assessed visual acuity at age 4.5 years.,PATIENT
335,Patients 54-89 years of age without previous filtering surgery with cataract and glaucoma who required lower levels of intraocular pressure (IOP).,PATIENT
336,Primary glaucoma triple procedure with and without MMC and YAG laser capsulotomy for posterior capsular opacification (PCO) was performed.,NON-PATIENT
337,"Individuals with a diagnosis of POAG, CACG, pseudoexfoliative glaucoma (PEXG), or pigmentary glaucoma (PG), with a recorded intraocular pressure (IOP) of more than 21 mmHg, visual field or optic disc changes characteristic of glaucoma, and taking the maximum tolerated dose of medication.",PATIENT
338,": Briefly, the eligibility criteria included 1) participants between the ages of 35 and 70 yrs, 2) candidates of lobectomy for non-small cell lung cancer, and 3) the first elective surgery of the day. Sixty-six patients were enrolled in the study.",PATIENT
339,Patients 18-85 years of age with medically uncontrolled glaucoma who had previous cataract and/or glaucoma surgery.,PATIENT
340,Intraocular pressure and AHF were measured in treated and contralateral control eyes.,NON-PATIENT
341,Twenty-four patients with glaucoma with elevated IOPs.,PATIENT
342,"The combination arm received oral osimertinib (80 mg, every day) plus intravenous bevacizumab (15 mg/kg, every 3 weeks) until progression or unacceptable toxic effects. The control arm received osimertinib monotherapy.",NON-PATIENT
343,A total of 258 patients undergoing RARC for bladder cancer.,PATIENT
344,Forty-eight patients with bilateral open angle glaucoma or ocular hypertension and intraocular pressure (IOP) greater than 22 mm Hg entered the study. Two of 28 patients receiving dorzolamide and two of 20 patients receiving placebo were withdrawn due to adverse experiences.,PATIENT
345,"In the Dex group, dexmedetomidine was given as an initial loading dose of 1.0  μg  kg(-1) over 10  min followed by a maintenance dose of 0.5  μg  kg(-1)  h(-1) during OLV while the control group was administered a comparable volume of 0.9% saline. Data were measured at 30  min (DEX-30) and 60  min (DEX-60) after dexmedetomidine or saline administration during OLV.",NON-PATIENT
346,"One thousand sixty one people who lived in areas of high socioeconomic deprivation, and either took medicines for diabetes, took antipsychotic medicines, or had chronic obstructive pulmonary disease (COPD). Of the 1053 who completed the study, just under half (49%) were Māori.",PATIENT
347,"Topical administration of study medication (fixed-combination brinzolamide, 1%, and brimonidine, 0.2%; brinzolamide, 1%; or brimonidine, 0.2%) 1 drop 3 times daily for 3 months.",NON-PATIENT
348,A total of 335 patients with bilateral ocular hypertension or open-angle glaucoma participated.,PATIENT
349,Sixty-three consecutive patients undergoing elective coronary artery bypass grafting with CPB were enrolled.,PATIENT
350,"After a 3-week run-in of timolol (TIMOPTIC; Merck & Co., Inc., Whitehouse Station, NJ) twice daily, eligible patients received either the combination (COSOPT; Merck & Co., Inc., Whitehouse Station, NJ) twice daily (plus placebo to ensure masking), timolol twice daily (plus placebo to ensure masking), or dorzolamide (TRUSOPT; Merck & Co. Inc., Whitehouse Station, NJ) three times daily for 3 months.",NON-PATIENT
351,Hospital outpatient diabetes clinic.,NON-PATIENT
352,"A total of 440 eligible patients were randomly assigned to groups as follows: A (control), 4 cycles of mitomycin/vindesine/cisplatin plus thoracic radiotherapy (TRT) of 60 Gy; B, weekly irinotecan/carboplatin for 6 weeks plus TRT of 60 Gy followed by 2 courses of irinotecan/carboplatin consolidation; or C, weekly paclitaxel/carboplatin for 6 weeks plus TRT of 60 Gy followed by 2 courses of paclitaxel/carboplatin consolidation.",NON-PATIENT
353,"Randomized, prospective and multicentre clinical trial.",NON-PATIENT
354,"The intervention group received comprehensive vision and eye examinations conducted by a study optometrist. The optometrist arranged for new eyeglasses for 92 subjects and referred 24 for a home visit with an occupational therapist, 17 for glaucoma management, and 15 for cataract surgery. The control group received usual care.",NON-PATIENT
355,All patients underwent vitreoretinal surgery and silicone oil exchange with or without membrane peeling and/or retinectomy. Patients were randomly allocated to perioperative infusion with or without 5-fluorouracil (200 microg/ml) and LMWH (5 IU/ml) in Hartmann's solution for 1 hour.,NON-PATIENT
356,A university-affiliated referral eye hospital.,NON-PATIENT
357,"The primary endpoint was time for resolution of DKA (pH ≥7.3, bicarbonate ≥15 mEq/L, beta-hydroxybutyrate <1 mmol/L). Secondary outcomes were the rate of fall in blood glucose until 250 mg/dL or less and the rate of complications (hypokalemia, hypoglycemia, and cerebral edema).",NON-PATIENT
358,"Baseline results from a randomized, controlled clinical trial.",NON-PATIENT
359,The sample population was randomly divided into 2 age- and gender-matched groups each of 18 patients. Group 1 received 0.005% latanoprost eyedrops once daily and the vehicle (placebo) once daily; group 2 was assigned to timolol 0.5% eyedrops twice daily.,NON-PATIENT
360,"A prospective, randomized, double-blinded trial.",NON-PATIENT
361,"Patients received unilateral trabeculectomy with either 4 subconjunctival injections of CAT-152 (100 microg in 100 microl phosphate buffer) or 4 placebo injections, administered immediately before and on completion of trabeculectomy, and on the first day and at 1 week after surgery. Patients were followed up for 12 months after surgery.",NON-PATIENT
362,Enrolled were 253 patients from 22 sites throughout the United States.,PATIENT
363,"The primary end point was progression-free survival (PFS) assessed by investigators. Secondary end points consisted of overall response rate, time to treatment failure, overall survival, and safety.",NON-PATIENT
364,"Thirty-two Asian patients with CACG, defined as glaucomatous optic neuropathy with a compatible visual field defect and at least 6 clock hours of synechial angle closure on gonioscopy were recruited. All patients had previous peripheral iridotomy (PI) with IOP >21 mmHg after PI and were thereafter controlled (IOP <22 mmHg) with one or two pressure-reducing drugs.",PATIENT
365,"The primary outcome of the study was exercise capacity. Secondary outcomes were muscle strength (Senior Fitness Test), health-related quality of life (Short-Form 36) and the postoperative outcomes. Patients were evaluated at baseline (before randomization), presurgery (only the prehabilitation group), after surgery and three months post-operatively.",NON-PATIENT
366,"Based on this analysis of recorded adjustments to inventory, various parameters were analyzed during the continued repurchase behavior program, including testimonials from buyers. With these figures, researchers judged on the patients' compliance rate to self-administer NAC eye-drops.",NON-PATIENT
367,"Exploratory analysis was performed on worsening of retinopathy, defined as 1 or more of the following: (1) worsening from no PDR to PDR, (2) worsening of 2 or more severity levels on reading center assessment of fundus photographs in eyes without PDR at baseline, (3) having panretinal photocoagulation, (4) experiencing vitreous hemorrhage, or (5) undergoing vitrectomy for the treatment of PDR.",NON-PATIENT
368,"The Age-Related Eye Disease Study 2 (AREDS2), a multicenter, randomized, double-masked, placebo-controlled phase 3 study with a 2 × 2 factorial design, conducted in 2006-2012 and enrolling 4203 participants aged 50 to 85 years at risk for progression to advanced AMD with bilateral large drusen or large drusen in 1 eye and advanced AMD in the fellow eye.",PATIENT
369,Six hundred sixteen men and women aged 70 and older (mean age 81) recruited mainly from people attending outpatient aged care services.,PATIENT
370,Patients were randomized to receive 1 acupuncture series (12 sessions with either eye-related [eye-points] or non-eye-related [non-eye-points] acupoints) and then crossed over to receive the other series.,NON-PATIENT
371,"Multicenter prospective, double-masked, controlled clinical trial conducted at 80 clinical sites. One hundred five surgeons enrolled 1090 participants undergoing corneal transplant for a moderate-risk condition, principally Fuchs dystrophy or pseudophakic or aphakic corneal edema (PACE). Forty-three eye banks provided corneas.",PATIENT
372,Secondary analysis of a group from a randomized trial.,NON-PATIENT
373,Difference in adherence before and after initiation of the intervention.,NON-PATIENT
374,"Patients were divided into 2 groups: (1) an intervention group receiving acupressure, and (2) a control group receiving standard care. The P6-Lu1-Lu10 acupuncture points in the hand, forearm, and chest were used, with acupressure being applied 2 times per day for 4 wk, for a total of 56 sessions.",NON-PATIENT
375,"Efficacy end points were VF and/or optic disc changes. Baseline demographic and clinical data were collected before randomization, except for corneal thickness measurements, which were determined during follow-up. Proportional hazards models were used to identify factors that predicted which participants in the EGPS had developed OAG.",NON-PATIENT
376,"A randomized, open-label, crossover study.",NON-PATIENT
377,Single university hospital.,NON-PATIENT
378,Participants were randomized to either a prehabilitation group or a control group. Participants in the prehabilitation group underwent a combination of moderate endurance and resistance training plus breathing exercises three to five times per week.,NON-PATIENT
379,"The time courses of MD, NB(ONH), and NB(fovea) in the eye with less negative MD.",NON-PATIENT
380,"IOP, complete success rate (IOP: ≥6 and ≤18 mmHg), visual acuity, use of medical therapy and systematic assessment of complications and postoperative interventions.",NON-PATIENT
381,Patients were randomized to receive intracameral TA or balanced salt solution at the end of surgery. Follow-up time was 6 months.,NON-PATIENT
382,"Nivolumab, 3 mg/kg intravenously every 2 weeks, with or without ipilimumab, 1 mg/kg intravenously every 6 weeks, until disease progression or intolerable toxic effects.",NON-PATIENT
383,"Patients were randomized (1:1:1) to receive 1 of the following regimens intravenously on a 21-day cycle: tislelizumab (200 mg, day 1) plus paclitaxel (175 mg/m2, day 1) and carboplatin (area under the concentration of 5, day 1) (arm A); tislelizumab plus nab-paclitaxel (100 mg/m2, days 1, 8, and 15) and carboplatin (arm B); and paclitaxel and carboplatin (arm C). Patients were stratified by disease stage and tumor programmed cell death 1 ligand 1 (PD-L1) expression (<1% vs 1%-49% vs ≥50%).",NON-PATIENT
384,"Multicenter, randomized, controlled trial.",NON-PATIENT
385,Randomized controlled clinical trial.,NON-PATIENT
386,"Primary efficacy and safety outcomes were coronary heart disease (CHD) and invasive breast cancer, respectively. A global index also included stroke, pulmonary embolism, colorectal cancer, endometrial cancer, hip fracture, and death.",NON-PATIENT
387,Tube shunt (350-mm(2) Baerveldt glaucoma implant) or trabeculectomy with mitomycin C (MMC 0.4 mg/mL for 4 minutes).,NON-PATIENT
388,"IOP, visual acuity, use of supplemental medical therapy, and failure (IOP >21 mm Hg or not reduced by 20%, IOP ≤5 mm Hg, reoperation for glaucoma, or loss of light perception vision).",NON-PATIENT
389,The primary outcome was sensitivity for mediastinal nodal (N2/N3) metastases. The reference standard was surgical pathological staging. Secondary outcomes were rates of unnecessary thoracotomy and complications.,NON-PATIENT
390,"Patients (age > or =30 years) were enrolled from 18 European centers. The patients fulfilled a series of inclusion criteria including the measurements of IOP (22-29 mmHg), two normal and reliable visual fields (VFs) (on the basis of mean defect and corrected pattern standard deviation/corrected loss of variance of standard 30/II Humphrey or Octopus perimetry), and normal optic disc as determined by the Optic Disc Reading Center (vertical and horizontal cup-to-disc ratios; asymmetry between the two eyes < or =0.4).",PATIENT
391,"One IOP measurement was made while patients were receiving their usual medications to lower IOP, and 3 IOP measurements were made at 8 am, 12 pm, and 4 pm after patients underwent washout of all IOP-lowering eyedrops.",NON-PATIENT
392,"The enrolled patients were randomized into an intervention or control group. Patients in the intervention group received perioperative breathing training, including deep breathing and coughing exercise, balloon-blowing exercise, and pursed lip breathing exercise. The control group received standard perioperative care without any breathing training.",NON-PATIENT
393,A prospective randomized study.,NON-PATIENT
394,"Pediatric patients of 3 age groups (<3, 3-<12, and 12-<18 years) and adults (≥18 years) receiving latanoprost ophthalmic solution 0.005% once daily in 1 or both eyes for ≥2 weeks.",PATIENT
395,Thirty-two eyes of 32 patients with medically uncontrolled POAG.,PATIENT
396,"The ongoing Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) enrolled and randomized 4763 adults with suspected or confirmed COVID-19 between March 9, 2020, and January 18, 2021, within at least 1 domain; 2011 critically ill adults were randomized to open-label interventions in the immunoglobulin domain at 129 sites in 4 countries. Follow-up ended on April 19, 2021.",PATIENT
397,Teaching hospital.,NON-PATIENT
398,"Patients 18 to 85 years of age who have undergone previous trabeculectomy, cataract extraction with intraocular lens implantation, or both and have inadequately controlled glaucoma with intraocular pressure (IOP) >or=18 mm Hg and <or=40 mm Hg on tolerated medical therapy.",PATIENT
399,Two-group parallel prospective randomised controlled trial.,NON-PATIENT
400,Patients were subdivided into 2 groups in each study and were treated with ripasudil or placebo twice daily for 8 weeks.,NON-PATIENT
401,"The primary outcome measure was reduction in IOP in the eye with higher IOP at baseline. Secondary outcome measures included safety variables (adverse events, ophthalmoscopy, biomicroscopy, iris pigmentation, laser-flare meter, visual acuity, visual fields, heart rate, blood pressure, blood chemistry, hematology, and urinalysis).",NON-PATIENT
402,"A prospective, controlled study that was randomized with respect to assignment to adjunctive MMC and a case-control design with respect to comparisons between SGTP and PGTP was studied.",NON-PATIENT
403,"A multicenter randomized clinical trial of 114 infants with unilateral congenital cataract in referral centers who were between ages 1 and 6 months at surgery. Mean follow-up was 4.8 years. This secondary analysis was conducted from December 23, 2004, to November 13, 2013.",PATIENT
404,Prospective randomized clinical trial.,NON-PATIENT
405,"The Age-Related Eye Disease Study 2 is a multicenter, double-masked randomized trial of 4203 participants, aged 50 to 85 years, at risk for developing late AMD; 66% of patients had bilateral large drusen and 34% had large drusen and late AMD in 1 eye.",PATIENT
406,Acetazolamide 250 mg twice daily from day 1 to day 18. Topical 50 micrograms/ml latanoprost or placebo eye drops bilaterally instilled once daily from day 4 to day 18.,NON-PATIENT
407,"Randomized clinical trial with recruitment from June 2004 to August 2007. The centralized, computer-generated, variable block size randomization scheme was stratified by treatment center and cancer stage. Participants, health care providers, and outcome assessors were not blinded to imaging modality assignment.",NON-PATIENT
408,Multicenter randomized clinical trial.,NON-PATIENT
409,Latanoprost acid plasma exposure.,NON-PATIENT
410,"Randomized, double-blind, placebo-controlled trial.",NON-PATIENT
411,Thoracic surgery ward and outpatient clinic in a teaching hospital.,NON-PATIENT
412,203 patients with lung cancer who had completed their initial treatment and were expected to survive for at least 3 months.,PATIENT
413,"Efficacy was evaluated by IOP measured at 10 am and 4 pm at baseline, month 1, and month 4.",NON-PATIENT
414,Asymptomatic or mildly symptomatic SARS-CoV-2 RNA positive vitamin D deficient (25(OH)D<20 ng/ml) individuals.,PATIENT
415,"Parallel, randomized, double-masked, and active-controlled study.",NON-PATIENT
416,"After informed consent, patients were randomized to treatment or no initial treatment with close follow-up. Treated patients had laser trabeculoplasty and started receiving topical betaxolol twice daily in eligible eyes. Follow-up visits include computerized perimetry and tonometry every 3 months and fundus photography every 6 months. Decisions to change or begin treatment are made jointly with the patient when EMGT progression occurs and also later if clinically needed.",NON-PATIENT
417,"Ultrasound biomicroscopy images were qualitatively assessed using standardized criteria. Plateau iris was defined in a quadrant by the presence of an anteriorly directed ciliary body, an absent ciliary sulcus, a steep iris root from its point of insertion followed by a downward angulation from the corneoscleral wall, presence of a central flat iris plane, and irido-angle contact. At least 2 quadrants had to fulfil the above criteria for an eye to be defined as plateau iris.",NON-PATIENT
418,"The primary outcome was incidence of grade 3 or higher chemotherapy-related toxic effects (graded using National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0). Secondary outcomes included advance directive completion, emergency department visits, unplanned hospitalizations, average length of stay, unplanned hospital readmissions, chemotherapy dose modifications, and early discontinuation. Overall survival analysis was performed up to 12 months after chemotherapy initiation.",NON-PATIENT
419,"Recruited patients were randomized into group 1 (phacoemulsification alone) or group 2 (combined phacotrabeculectomy with adjunctive mitomycin C). Postoperatively, patients were reviewed every 3 months for 2 years.",NON-PATIENT
420,10 clinical centers in the United States and Canada.,NON-PATIENT
421,"Intraocular pressure (IOP) was measured at morning trough (hour 0) and peak (2 hours postdose) on day 1, week 2, and months 1, 2, and 3. Ocular and systemic safety were evaluated at each study visit.",NON-PATIENT
422,The Lung Health Study was a randomized clinical trial of smoking cessation. Special intervention participants received the smoking intervention program and were compared with usual care participants. Vital status was followed up to 14.5 years.,NON-PATIENT
423,Patients were assigned randomly either to Nd:YAG LPI or to a control group (no laser).,NON-PATIENT
424,"The primary end point was blinded independent review committee-assessed progression-free survival (PFS). Secondary end points included systemic and intracranial response, time to central nervous system progression, and overall survival. Efficacy was evaluated in the intent-to-treat (ITT) population as well as a prespecified modified ITT (mITT) population consisting of patients with central laboratory-confirmed ALK-positive NSCLC.",NON-PATIENT
425,Either surgical staging or endosonography (combined transesophageal and endobronchial ultrasound [EUS-FNA and EBUS-TBNA]) followed by surgical staging in case no nodal metastases were found at endosonography. Thoracotomy with lymph node dissection was performed when there was no evidence of mediastinal tumor spread.,NON-PATIENT
426,Randomized single-blinded study.,NON-PATIENT
427,"Randomized, multicenter, double-masked clinical trial.",NON-PATIENT
428,"Pediatric critical care division of a tertiary care hospital from October, 2014 to July, 2018.",PATIENT
429,"Study participants were initially randomized to 6 monthly intravitreal injections of aflibercept or bevacizumab. At month 6, protocol-defined good responders were rerandomized to continued monthly or treat-and-extend dosing of their originally assigned study drug, and protocol-defined poor or marginal responders were switched to alternative treatment. After month 12, participants were treated as per investigator discretion.",NON-PATIENT
430,"Intraocular pressure (IOP) was recorded at all follow-up dates, together with visual field examination and optic disc evaluation twice yearly.",NON-PATIENT
431,"Patients were randomly divided into 2 groups (n = 20 in each group). Both groups received general anesthesia with enflurane combined with epidural blockade. At 5 minutes before skin incision, patients were given either tramadol 1.5 mg/kg intravenously (IV), followed by a continuous infusion of 0.5 mg/kg per hour until the end of surgery (group I), or IV normal saline (group II).",NON-PATIENT
432,Participants were patients in the unit who were receiving chemotherapy and had experienced dyspnea.,PATIENT
433,"The study was performed at a university hospital in Istanbul, Turkey.",NON-PATIENT
434,"Recruited patients were randomized into group 1 (phacoemulsification alone) or group 2 (combined phacotrabeculectomy with adjunctive mitomycin C). Postoperatively, patients were reviewed every 3 months for 2 years.",NON-PATIENT
435,"Double-masked, prospective, randomized, placebo-controlled clinical trial.",NON-PATIENT
436,"Physiotherapeutic Resources Lab, Department of Health Sciences, Ribeirão Preto Medical School, University of São Paulo.",NON-PATIENT
437,Thirty consecutive patients requiring trabeculectomy for uncontrolled primary glaucoma.,PATIENT
438,"Smokers were enrolled in a pretest-posttest trial, and randomized to 1 of 3 cessation services.",NON-PATIENT
439,Eyes were assigned randomly either to trabeculectomy with mitomycin C or to viscocanalostomy in combination with phacoemulsification and intraocular lens implantation.,NON-PATIENT
440,Change in visual field and any ocular or systemic complications.,NON-PATIENT
441,"A randomized, placebo-controlled, double-masked, single-center trial.",NON-PATIENT
442,The primary efficacy variable was intraocular pressure (IOP).,NON-PATIENT
443,Four hundred and forty-one adults awaiting elective upper abdominal surgery attending pre-anaesthetic clinics at three public hospitals in Australia and New Zealand.,PATIENT
444,Subjects were assigned randomly to receive a continuous thoracic epidural or paravertebral infusion. Patients in the epidural group were randomized to receive either bupivacaine alone or in combination with hydromorphone. Visual analog scores as well as incentive spirometery results were obtained before and after thoracotomy.,NON-PATIENT
445,Patients were randomized to receive either single- or two-quadrant conjunctival peritomy and phacoemulsification.,NON-PATIENT
446,setting: Multicenter clinical trial conducted in 60 centers in the United States and Europe.,NON-PATIENT
447,Two hundred ninety-three patients with ocular hypertension or primary open-angle glaucoma participated.,PATIENT
448,"Prospective, randomized, controlled, open single-center study.",NON-PATIENT
449,"Patients were randomly assigned to one of the following two groups: oxycodone and dexmedetomidine (group OD) or oxycodone alone (group O). Before induction of anesthesia, patients in group OD received 0.5 μg/kg, dexmedetomidine diluted to 20 mL with physiologic saline and infused for 10 minutes intravenously. The PCA protocol was 50 mg of oxycodone and 0.05 μg/kg/h dexmedetomidine diluted to 100 mL. Patients in group O received 20 mL of physiologic saline infused for 10 minutes. Their PCA protocol consisted of 50 mg of oxycodone diluted to 100 mL. Intravenous PCA was used for postoperative analgesia (lasting for 48 h).",NON-PATIENT
450,"Analysis of visual field decay during a prospective, randomized clinical trial comparing primary laser trabeculoplasty with medication.",NON-PATIENT
451,"The primary outcome measure was defined as posterior retinal reattachment after removal of silicone oil without any reoperations at 6 months. Secondary outcome measures recorded were posterior retinal reattachment, localized/tractional retinal detachment, visual acuity, macular pucker, hypotony, glaucoma, keratopathy, and cataract. Removal of silicone oil and reoperations were also recorded.",NON-PATIENT
452,"Community in Sydney, Australia.",NON-PATIENT
453,Patients took isotretinoin at a high dose (1.0 mg/kg per day) or a moderate dose (0.5 mg/kg per day) or placebo. Group 1 took the high dose for 1 year and then the moderate dose for 2 years. Group 2 took the moderate dose for 3 years. Group 3 took placebo for 3 years.,NON-PATIENT
454,Consecutive patients (aged≥20 years) who reported moderate-to-severe pain after effectual 2-day epidural analgesia post-thoracotomy for lung cancer from February 2012 to March 2013.,PATIENT
455,"Randomized, clinical trial.",NON-PATIENT
456,"A total of 27,347 postmenopausal women aged 50 to 79 years were enrolled at 40 US centers.",PATIENT
457,"IOP, conjunctival hyperemia.",NON-PATIENT
458,"Randomized, double-blind controlled clinical trial.",NON-PATIENT
459,"Overall 63 patients underwent VATS were randomly assigned to a triaging (TG, ",PATIENT
460,Thirty-six patients affected with bilateral pigmentary glaucoma controlled with no more than a single hypotensive medication were enrolled in the study.,PATIENT
461,Seventy-four patients with cataract and without evidence of glaucoma were studied.,PATIENT
462,"A two group (intervention and control) by five time points (baseline, pre-cycle 2, pre-cycle 3, pre-cycle 4 and pre-cycle 5) randomised controlled trial.",NON-PATIENT
463,Specialist cancer hospital and three cancer units in southeastern England.,NON-PATIENT
464,Thirty-four subjects with primary open-angle glaucoma or ocular hypertension were enrolled.,PATIENT
465,"Patients underwent routine trabeculectomy. In group 1, mitomycin-C (0.05 mg/ml) was applied topically to the filtering bleb on days 1, 2, and 3 after surgery (postoperative application). In group 2, mitomycin-C (0.2 mg/ml) was applied by means of to a sponge during surgery (intraoperative application).",NON-PATIENT
466,"Patients received bimatoprost 0.03% ophthalmic solution once daily (8 PM, with vehicle control at 8 AM), bimatoprost 0.03% twice daily (8 AM; 8 PM), or timolol 0.5% twice daily (8 AM; 8 PM) in an uneven 2:2:1 randomization. Scheduled visits were at prestudy, baseline (day 0), weeks 2 and 6, and month 3. Intraocular pressure (IOP) was measured at 8 AM (predose), 10 AM, and 4 PM.",NON-PATIENT
467,"Trabeculectomy combined with phacoemulsification and a small incision (5 x 6 mm), all polymethylmethacrylate posterior chamber intraocular lens implantation with or without adjunctive MMC (0.5 mg/ml for 1 minute), was performed.",NON-PATIENT
468,450 black Africans with primary glaucoma.,PATIENT
469,"Proportions of eyes with a 2-step or greater improvement in DRSS level, vision-threatening complications, and center-involved DME from baseline to weeks 24, 52, and 100.",NON-PATIENT
470,"Diurnal IOP curves; ophthalmologic evaluations including corneal ultrasound pachymetry and endothelial cell count; and systemic evaluations including vital signs, blood chemistries, complete blood cell counts, urinalysis, electrocardiogram, and drug and carbonic anhydrase activity levels in red blood cells.",NON-PATIENT
471,University hospital.,NON-PATIENT
472,"Patients were randomized to platinum-based chemotherapy, concurrent with chest radiotherapy (60-63 Gy), with or without consolidation chemotherapy or the same treatment plus metformin, 2000 mg/d, during chemoradiotherapy and afterward for up to 12 months.",NON-PATIENT
473,Randomized controlled clinical trial.,NON-PATIENT
474,Four clinical sites.,NON-PATIENT
475,"The Oberstaufen Schrothkur included a low-calorie diet, daily changes between a higher or lower fluid intake, daily alternation in physical activities, and daily application of cold and damp body packs. The diabetes-friendly holiday included a holiday stay specifically tailored to diabetics.",NON-PATIENT
476,Astigmatism and high astigmatism at each study visit.,NON-PATIENT
477,This parallel randomized clinical trial of monthly block randomization included patients in the UCLA Health system who underwent thyroid biopsy from August 2017 to January 2020 with indeterminate cytology (Bethesda System for Reporting Thyroid Cytopathology category III or IV).,PATIENT
478,"The SGTP group consisted of 49 eyes of 49 consecutive patients with primary open-angle glaucoma with a history of glaucoma filtration surgery requiring glaucoma medical therapy and in need of cataract surgery, randomized to adjunctive MMC (SGTP MMC subgroup of 21 eyes) and no adjunctive MMC (SGTP control subgroup of 28 eyes). The PGTP group consisted of 49 PGTP cases closely matched to the SGTP cases with respect to age, race, gender, MMC use, C:D ratio, and systemic diseases.",PATIENT
479,"Quality of life was measured by the Functional Assessment of Chronic Illness Therapy for Palliative Care (score range, 0-184). Symptom intensity was measured by the Edmonton Symptom Assessment Scale (score range, 0-900). Mood was measured by the Center for Epidemiological Studies Depression Scale (range, 0-60). These measures were assessed at baseline, 1 month, and every 3 months until death or study completion. Intensity of service was measured as the number of days in the hospital and in the intensive care unit (ICU) and the number of emergency department visits recorded in the electronic medical record.",NON-PATIENT
480,"A prospective, randomized, controlled trial was carried out to determine the efficacy of an extended course (5 days) of intravenous amoxicillin-clavulanic acid in reducing the rate of atelectasis and pulmonary infections postoperatively. Other possible risk factors that might predispose to pulmonary complications were also evaluated.",NON-PATIENT
481,PET-CT or conventional staging (abdominal CT and bone scan). All patients also had cranial imaging using CT or magnetic resonance imaging.,NON-PATIENT
482,Sixty patients with refractory glaucoma.,PATIENT
483,"A short-term, randomized, placebo-controlled, double-masked study.",NON-PATIENT
484,Patients were randomly assigned to receive either lung-protective ventilation (LPV group) [tidal volume 5 ml kg ideal body weight + PEEP between 5 and 8 cmH2O] or nonprotective ventilation (control group) (tidal volume 10 ml kg ideal body weight without PEEP) during anaesthesia.,NON-PATIENT
485,"IOP, blood pressure (BP), heart rate (HR), best-corrected visual acuity (BCVA), visual field (VF), optic disc and peripapillary retinal nerve fiber layer (RNFL) measurements, compliance, and adverse reactions. Probability to detect 3 mm Hg IOP difference between series was 90%.",NON-PATIENT
486,"Mean intraocular pressure (IOP), postoperative medications, visual acuity, filtering bleb appearance, and complications.",NON-PATIENT
487,A prospective randomized double-blinded study.,NON-PATIENT
488,Maintenance chemotherapy or SAbR to all sites of gross disease (including SAbR or hypofractionated radiation to the primary) followed by maintenance chemotherapy.,NON-PATIENT
489,"Randomized, controlled, observer-masked clinical trial.",NON-PATIENT
490,"IOP, complication rates, visual acuity, visual field, quality of life, reoperations for glaucoma, and need for supplemental medical therapy.",NON-PATIENT
491,Randomized clinical trial.,NON-PATIENT
492,Fifty consecutive patients scheduled for glaucoma surgery in one large surgical center.,PATIENT
493,Seven clinical sites in the UK; five specialist cancer centres and two local district hospitals.,NON-PATIENT
494,"Seventy-three eyes of 64 consecutive patients with their first presentation of acute PACG, with intraocular pressure (IOP) levels of 40 mmHg or more, were recruited into the study.",PATIENT
495,A randomized controlled trial.,NON-PATIENT
496,"Patients underwent routine trabeculectomy, with or without phacoemulsification and intraocular lens implantation. In the study group (n = 28), sodium hyaluronate 2.3% was injected between the scleral and conjunctival flaps at the conclusion of the surgery. In the control group (n = 27), balanced salt solution (BSS) was injected in the same fashion, in an unmasked design.",NON-PATIENT
497,"Patients were assigned to 2 groups: control (control treatment: acetaminophen, 400 mg, and codeine phosphate powder, 20 mg) or pregabalin (pregabalin, 75 mg, plus control treatment). The 12-week study period included 2-week study treatment and 10-week follow-up.",NON-PATIENT
498,Patients were randomized 1:1 to receive polyquaternium-1-preserved travoprost 0.003% (n = 442) or benzalkonium chloride-preserved travoprost 0.004% (n = 422) once daily for 3 months.,NON-PATIENT
499,"Participants in the intervention group were offered annual posteroanterior view chest radiograph for 4 years. Diagnostic follow-up of positive screening results was determined by participants and their health care practitioners. Participants in the usual care group were offered no interventions and received their usual medical care. All diagnosed cancers, deaths, and causes of death were ascertained through the earlier of 13 years of follow-up or until December 31, 2009.",NON-PATIENT
500,"Intraocular pressure (IOP) was measured at morning trough (hour 0) and peak (2 hours postdose) on day 1, week 2, and months 1, 2, and 3. Ocular and systemic safety were evaluated at each study visit.",NON-PATIENT
501,"The primary end point was disease-free survival (DFS). Secondary end points included overall survival (OS), locoregional recurrence-free survival (LRFS), distant metastasis-free survival, and toxic effects.",NON-PATIENT
502,"Phase 1, open-label, multicenter study.",NON-PATIENT
503,"Randomized, double-masked, controlled, observational clinical trial.",NON-PATIENT
504,"Perioperative parameters included transcutaneous oxygen saturation (SpO2), hemodynamic data, extravascular lung water index (EVLWI), pulmonary vascular permeability index (PVPI) as determined by the single-indicator transpulmonary thermodilution technique, and partial pressure of arterial oxygen/inspired oxygen fraction (PaO2/FIO2) ratio.",NON-PATIENT
505,"Patients were randomized to either laser trabeculoplasty plus topical betaxolol hydrochloride (n = 129) or no initial treatment (n = 126). Study visits included Humphrey Full Threshold 30-2 visual field tests and tonometry every 3 months, and optic disc photography every 6 months. Decisions regarding treatment were made jointly with the patient when progression occurred and thereafter.",NON-PATIENT
506,"The research team designed a single-blinded, randomized, controlled clinical trial.",NON-PATIENT
507,Participants were assigned randomly to one of two treatment groups.,NON-PATIENT
508,"Patients were randomly assigned to two groups. Group C consisted of 18 patients whose nondependent lung was kept collapsed during OLV, while Group IR included 18 patients with IR that consisted of 4 separate, 10-second manual inflations and 5-second openings within one minute at intervals of 20 minutes during OLV.",NON-PATIENT
509,A teaching hospital.,NON-PATIENT
510,"This was a prospective, open-label, two-protocol clinical study.",NON-PATIENT
511,"Randomized controlled multicenter trial (Ghent, Leiden, Leuven, Papworth) conducted between February 2007 and April 2009 in 241 patients with resectable (suspected) NSCLC in whom mediastinal staging was indicated based on computed or positron emission tomography.",PATIENT
512,"Prospective, randomized study.",NON-PATIENT
513,Implantation of the iStent trabecular micro-bypass stent in conjunction with cataract surgery or cataract surgery only.,NON-PATIENT
514,"A multisite randomized clinical trial with site-level 1-to-1 allocation into 2 conditions was conducted in 4 US health care systems. A total of 433 individuals who were currently smoking and reported at enrollment that they were not ready to quit smoking were enrolled. The study was conducted from November 7, 2016, to July 31, 2020.",PATIENT
515,"Prospective, randomized clinical study.",NON-PATIENT
516,"670 patients with pathologically confirmed stage IIIb-IV NSCLC, unfit for chemotherapy, predominantly poor performance status (>2 on Eastern Cooperative Oncology Group, ECOG) and estimated life expectancy of at least 8 weeks. Patients were followed until disease progression or death, including a subgroup of patients who developed first cycle rash.",PATIENT
517,"Randomised controlled trial with concealed allocation, intention-to-treat analysis and blinded assessment of the primary outcome.",NON-PATIENT
518,"Prospective, randomized, placebo-controlled, double-masked cross-over trial.",NON-PATIENT
519,"Consecutive patients younger than 80 years with planned surgery for carcinoma of the oral cavity, pharynx, or larynx were enrolled. Patients with diabetes, those who had received antibiotics within 1 week before surgery, and those with preexisting pulmonary disease were excluded.",PATIENT
520,Time to first quit attempt (duration from TAB experience to primary outcome) and carbon monoxide level-verified smoking cessation at 6-month follow-up. All analyses used an intention-to-treat approach.,NON-PATIENT
521,"Intervention and control groups both participated every other week in one 45-min structured cardiovascular risk reduction educational session over the course of 1 year. During alternative weeks, sessions comprised blood pressure checks, coupled with individualized support discussions focused on challenges and identified obstacles to adherence. In addition to the aforementioned sessions, the intervention group participated in a novel gospel music program with weekly, 45-minute vocal and instrumental sessions.",NON-PATIENT
522,"Eyes were assigned randomly to either viscocanalostomy (group 1) or trabeculectomy (group 2) with no intraoperative antifibrotics in the study eye. In group 1, no further intervention was allowed, whereas trabeculectomy eyes could receive subconjunctival 5-fluorouracil (5-FU) injections or laser suture lysis after surgery.",NON-PATIENT
523,"The primary end point was progression-free survival (PFS) assessed by modified Response Evaluation Criteria in Solid Tumors (RECIST) (target hazard ratio, 0.60). Secondary end points were overall survival (OS), tumor response rate, safety, and quality of life, analyzed by intention to treat. We measured plasma arginine and citrulline levels, anti-ADI-PEG20 antibody titer, ASS1 methylation status, and metabolic response by 18F-fluorodeoxyglucose positron-emission tomography.",NON-PATIENT
524,A total of 346 patients undergoing lobectomy or pneumonectomy for lung cancer.,PATIENT
525,"Tonometry and tonography were assessed before surgery and at 1 day, 1 week, 6 weeks, and 1 year after surgery by a masked observer.",NON-PATIENT
526,Smokers aged 18 to 30 (n = 3094) were recruited through online and off-line methods and from telephone quit lines and analyzed.,PATIENT
527,"Randomized controlled trial conducted from November 2003 through May 2008 of 322 patients with advanced cancer in a rural, National Cancer Institute-designated comprehensive cancer center in New Hampshire and affiliated outreach clinics and a VA medical center in Vermont.",PATIENT
528,"Patients were randomized to two groups of 23 patients each and were received sevoflurane (group SEV) or isoflurane (group ISO) during surgery, respectively. In vitro, lung cancer cells were treated with platelets in the presence or absence anesthetics.",NON-PATIENT
529,"The primary ordinal end point was organ support-free days (days alive and free of intensive care unit-based organ support) up to day 21 (range, -1 to 21 days; patients who died were assigned -1 day). The primary analysis was an adjusted bayesian cumulative logistic model. Superiority was defined as the posterior probability of an odds ratio (OR) greater than 1 (threshold for trial conclusion of superiority >99%). Futility was defined as the posterior probability of an OR less than 1.2 (threshold for trial conclusion of futility >95%). An OR greater than 1 represented improved survival, more organ support-free days, or both. The prespecified secondary outcomes included in-hospital survival; 28-day survival; 90-day survival; respiratory support-free days; cardiovascular support-free days; progression to invasive mechanical ventilation, extracorporeal mechanical oxygenation, or death; intensive care unit length of stay; hospital length of stay; World Health Organization ordinal scale score at day 14; venous thromboembolic events at 90 days; and serious adverse events.",NON-PATIENT
530,"Corneas from donors younger than 66 years and donors 66 years or older were assigned, masked to donor age. Surgery and postoperative care were performed according to the surgeons' usual routines. Participants were followed up for as long as 12 years.",NON-PATIENT
531,Randomised controlled trial.,NON-PATIENT
532,Adult patients with open-angle glaucoma or ocular hypertension. One eye per patient was analyzed.,PATIENT
533,"A secondary analysis (performed in September 2014) of the Japanese Radiation Oncology Study Group (JROSG) 99-1, a phase 3 randomized trial, comparing SRS alone and whole-brain radiotherapy (WBRT) + SRS conducted in 1999 to 2003. Among a total of 132 patients, 88 with non-small-cell lung cancer (NSCLC) and 1 to 4 BMs were included and poststratified by DS-GPA scores to avoid potential bias from BMs from different primary cancer types. The median follow-up time was 8.05 months.",PATIENT
534,Parallel group randomized controlled feasibility trial.,NON-PATIENT
535,A multicentre trial from December 2008 to October 2011.,NON-PATIENT
536,"Sixty eyes of 60 Asian patients undergoing extracapsular cataract extraction with intraocular lens implantation were examined. Of these, 28 eyes of 28 patients served as control eyes. Patients were stratified for age and presence of diabetes mellitus.",PATIENT
537,A three-group randomized controlled trial.,NON-PATIENT
538,The study consisted of 40 eyes of 40 patients with uncontrolled exfoliation glaucoma without a history of previous intra- or extraocular surgery and in need of cataract surgery.,PATIENT
539,"After an open-label 3-week 0.5% timolol run-in period, patients with an hour 2 intraocular pressure (IOP) of > or = 22 mmHg were randomly assigned to receive either the dorzolamide/timolol combination twice daily or the concomitant use of brimonidine twice daily and timolol twice daily (brimonidine + timolol) for 6 months.",NON-PATIENT
540,Individual supplements of 400 IU of vitamin E every other day and 500 mg of vitamin C daily.,NON-PATIENT
541,Fifteen patients underwent trabeculectomy with permanent interrupted sutures; the same number underwent trabeculectomy with releasable sutures.,NON-PATIENT
542,Intraocular pressure (IOP) and requirement for topical glaucoma drugs.,NON-PATIENT
543,A total of 108 patients with POAG or OH were enrolled.,PATIENT
544,Prospective randomized trial.,NON-PATIENT
545,"Randomized, crossover, cross-sectional, clinical trial.",NON-PATIENT
546,"Randomization 2:1 to arginine deprivation (ADI-PEG20, 36.8 mg/m2, weekly intramuscular) plus best supportive care (BSC) or BSC alone.",NON-PATIENT
547,Individuals with central-involved diabetic macular edema causing visual acuity impairment.,PATIENT
548,The main outcomes were symptoms and severity of diabetic neuropathy. Further outcomes were fasting blood sugar and glycosylated hemoglobin.,NON-PATIENT
549,Patients undergoing lung cancer resection (N=24).,PATIENT
550,This post hoc analysis of a randomized clinical trial conducted at 39 DRCR Retina Network sites included adults with vision loss due to PDR-related vitreous hemorrhage for whom vitrectomy was considered. Data were collected from November 2016 to January 2020.,PATIENT
551,"The Ontario Clinical Oncology Group Advanced Lung Cancer Treatment With Metformin and Chemoradiotherapy (OCOG-ALMERA) study was a multicenter phase 2 randomized clinical trial. Patients were stratified for stage IIIA vs IIIB LA-NSCLC and use of consolidation chemotherapy. The trial was designed to enroll 96 patients with unresected LA-NSCLC who did not have diabetes. The trial was conducted from September 24, 2014, to March 8, 2019.",PATIENT
552,"The investigators compare the baseline demographic, medical, and ophthalmic characteristics of black and white patients, adjusting the comparisons for age and gender.",NON-PATIENT
553,Visual field reliability and global VF indices were measured.,NON-PATIENT
554,"Efficacy end points were visual field, optic disc changes, or both. A visual field change during follow-up had to be confirmed by 2 further positive tests. Optic disc change was defined on the basis of the agreement of 2 of 3 independent observers evaluating optic disc stereo slides. The safety end point was an IOP of more than 35 mmHg on 2 consecutive examinations.",NON-PATIENT
555,Low-dose (0.05 Unit/kg/hour) vs. Standard-dose (0.1 Unit/kg/hour) insulin infusion.,NON-PATIENT
556,"Double-blind, randomized, crossover study.",NON-PATIENT
557,"A multicomponent, psychoeducational intervention (Project ENABLE [Educate, Nurture, Advise, Before Life Ends]) conducted by advanced practice nurses consisting of 4 weekly educational sessions and monthly follow-up sessions until death or study completion (n = 161) vs usual care (n = 161).",NON-PATIENT
558,Chemoradiation and consolidation chemotherapy with or without metformin.,NON-PATIENT
559,Seventeen clinical centers.,NON-PATIENT
560,Randomised controlled trial.,NON-PATIENT
561,"The primary outcome was the occurrence of major postoperative complications (pneumonia, acute lung injury, acute respiratory distress syndrome, pulmonary embolism, shock, myocardial infarction or death) within 30 days after surgery.",NON-PATIENT
562,setting: Sixteen international clinical centers.,NON-PATIENT
563,"S Documented development of late AMD by central, masked grading of annual retinal photographs or by treatment history. RESULTS In exploratory analysis of lutein/zeaxanthin vs no lutein/zeaxanthin, the hazard ratio of the development of late AMD was 0.90 (95% CI, 0.82-0.99; P = .04). Exploratory analyses of direct comparison of lutein/zeaxanthin vs beta carotene showed hazard ratios of 0.82 (95% CI, 0.69-0.96; P = .02) for development of late AMD, 0.78 (95% CI, 0.64-0.94; P = .01) for development of neovascular AMD, and 0.94 (95% CI, 0.70-1.26; P = .67) for development of central geographic atrophy. In analyses restricted to eyes with bilateral large drusen at baseline, the direct comparison of lutein/zeaxanthin vs beta carotene showed hazard ratios of 0.76 (95% CI, 0.61-0.96; P = .02) for progression to late AMD, 0.65 (95% CI, 0.49-0.85; P = .002) for neovascular AMD, and 0.98 (95% CI, 0.69-1.39; P = .91) for central geographic atrophy.",NON-PATIENT
564,"Patients were randomized into undergoing either phacoemulsification or trabeculectomy with adjunctive mitomycin C. After surgery, patients were followed up every 3 months for 2 years.",NON-PATIENT
565,Eyes were randomized to receive intravitreal injection of bevacizumab (1.25 mg; n = 182) or aflibercept (2.0 mg; n = 180) every 4 weeks through month 6.,NON-PATIENT
566,"This open-label, randomized phase 3 clinical trial was conducted at 46 sites in China between July 2018 and June 2019 and included patients with treatment-naive, histologically confirmed stage IIIB/IV sq-NSCLC. The data cutoff for these analyses was December 6, 2019; data extraction occurred on January 7, 2020.",PATIENT
567,"The primary outcome was 1-year progression-free survival (PFS), designed to detect 15% improvement in 1-year PFS from 50% to 65% (hazard ratio [HR], 0.622). Secondary end points included overall survival, time to local-regional recurrence, time to distant metastasis, and toxicity per Common Terminology Criteria for Adverse Events, version 4.03.",NON-PATIENT
568,Intraocular pressure (IOP) and requirement for glaucoma drugs.,NON-PATIENT
569,"Newly diagnosed patients 50 to 80 years of age with early glaucomatous visual field defects were mainly identified from a population-based screening of more than 44,000 residents of Malmö and Helsingborg, Sweden. Exclusion criteria were advanced visual field loss; mean IOP greater than 30 mmHg or any IOP greater than 35 mmHg; visual acuity less than 0.5; and inability to complete follow-up protocols.",PATIENT
570,"Confirmed newly diagnosed invasive cancer at any site, except for nonmelanoma skin cancer. Incidence of breast, colorectal, and lung cancer were secondary end points.",NON-PATIENT
571,"Mean diurnal, peak, trough, IOP range (peak - trough), and standard deviation (SD) of IOP measurements, and mean deviation (MD) and corrected pattern SD (CPSD) of VF examinations.",NON-PATIENT
572,"A total of 200 eyes of 200 consecutive primary open-angle glaucoma patients who had undergone primary PT with capsular bag implantation of either a silicone IOL (102 eyes) or an acrylic IOL (98 eyes) according to the initial short-term prospective, randomized study protocol.",PATIENT
573,"IOP, visual acuity, and reoperation for glaucoma.",NON-PATIENT
574,"Five hundred twenty-three patients with open-angle glaucoma or ocular hypertension, 17 to 85 years of age. Patients currently using ocular hypotensive medications were required to undergo a washout.",PATIENT
575,The primary efficacy variable was diurnal intraocular pressure.,NON-PATIENT
576,One hundred sixteen eyes of 116 patients with PDS and OHT.,PATIENT
577,"Eyes were randomly assigned to receive intraoperative mitomycin-C (0.3 mg/ml) applied under the conjunctival flap (group 1), scleral flap (group 2), or under both flaps (group 3).",NON-PATIENT
578,Randomized clinical trial.,NON-PATIENT
579,There was no intervention performed.,NON-PATIENT
580,"Randomized, multicenter, controlled clinical trial.",NON-PATIENT
581,"Prospective, randomized clinical trial.",NON-PATIENT
582,"The diagnosis of a second primary malignancy of the head and neck, lung, or bladder was regarded as the end point signifying failure of therapy. Issues of drug adverse effect profile and impact on survival were measured.",NON-PATIENT
583,"We conducted 2, multicenter, randomized, double-masked, parallel group comparison studies of ripasudil-timolol and ripasudil-latanoprost in 29 and 36 Japanese clinical centers, respectively. Analyses were performed on an intention-treat-treat basis. After appropriate run-in periods with timolol or latanoprost, 208 and 205 patients whose IOP levels were 18 mm Hg or higher were enrolled in the ripasudil-timolol and ripasudil-latanoprost groups, respectively. Enrollment began December 1, 2011, and follow-up was completed on September 7, 2012, in the ripasudil-timolol study. Enrollment began December 1, 2011, and follow-up was completed on September 27, 2012, in the ripasudil-latanoprost study.",PATIENT
584,Three U.K. hospitals.,NON-PATIENT
585,"Multicenter, randomized, double-masked, parallel-group phase 4 clinical trial.",NON-PATIENT
586,33 U.S. screening centers.,NON-PATIENT
587,"In the Women's Health Study conducted between 1992 and 2004, 39 876 apparently healthy US women aged at least 45 years were randomly assigned to receive vitamin E or placebo and aspirin or placebo, using a 2 x 2 factorial design, and were followed up for an average of 10.1 years.",PATIENT
588,"Patients were randomly assigned to either initial medical therapy or initial trabeculectomy. After treatment initiation and early follow-up, patients received clinical and QOL evaluations at 6-month intervals. QOL assessments were administered by telephone at a centralized interviewing center.",NON-PATIENT
589,A 350-mm(2) Baerveldt glaucoma implant or trabeculectomy with mitomycin C (MMC 0.4 mg/ml for 4 minutes).,NON-PATIENT
590,Community- and university-based ophthalmology practices.,NON-PATIENT
591,Eligible patients were randomized to hypofractionated IGRT (60 Gy in 15 fractions) vs CFRT (60 Gy in 30 fractions).,NON-PATIENT
592,"Randomization of both eyes to double-masked monotherapy with brimonidine or timolol. Follow-up visits included Humphrey 24-2 full-threshold perimetry, tonometry every 4 months, and annual optic disc photography.",NON-PATIENT
593,"A single-masked, two-center, crossover comparison with two 6-week treatment periods occurring after at least a 3-week medicine-free period. Diurnal curve intraocular pressures were taken at 2:00 AM, 6:00 AM, 10:00 AM, 2:00 PM, 6:00 PM, and 10:00 PM.",NON-PATIENT
594,"The IOP-lowering effects at hour 0 and hour 2 were collected at 1, 3, and 6 months. We hypothesized that both treatment regimens would have comparable hour 2 IOP-lowering effects at month 3. The treatments were considered comparable if the two-sided 95% confidence interval of the treatment difference was within +/- 1.5 mmHg. Tolerability data were also collected at 1, 3, and 6 months.",NON-PATIENT
595,"Functional parameters assessed before and after 4 weeks of PR or CPT (phase 1), and pulmonary complications assessed after lung cancer resection (phase 2).",NON-PATIENT
596,"In this phase 3, double-masked, parallel-group, multicenter study, eligible patients were randomized 1:1:1 to treatment with fixed-combination brinzolamide, 1%, and brimonidine, 0.2%; brinzolamide, 1%; or brimonidine, 0.2%, 3 times daily for 3 months.",NON-PATIENT
597,Adults with uncontrolled primary open angle or pseudoexfoliation glaucoma randomized into 2 groups.,PATIENT
598,Diagnostic test performance of the RNA test compared with the DNA-RNA test. The secondary outcome was comparison of test performance with prior versions of the molecular tests.,NON-PATIENT
599,Fifty-one medically uncontrolled CACG eyes with coexisting cataract of 51 patients.,PATIENT
600,"We evaluated IOP, IOP change from baseline, and the number of eyes requiring surgery after the addition of study medication.",NON-PATIENT
601,The supervised and home training groups performed two weekly sessions of proprioceptive exercises for 12 weeks. The control group was not submitted to any of treatment.,NON-PATIENT
602,The primary outcome was the effect of dexmedetomidine on oxygenation. The secondary outcome was the effect of dexmedetomidine administration on postoperative pulmonary complications.,NON-PATIENT
603,Randomized clinical trial.,NON-PATIENT
604,"Adherence with administered medication, as recorded by the dosing aids.",NON-PATIENT
605,"Intraocular pressure profile, corneal clarity, symptoms, visual acuity, angle status by indentation gonioscopy, and complications of treatment.",NON-PATIENT
606,"A total of 332 black patients (451 eyes), 249 white patients (325 eyes), and 10 patients of other races (13 eyes) with open-angle glaucoma that could not be controlled by medical therapy alone participated.",PATIENT
607,"A parallel-group, single-blind randomized clinical trial.",NON-PATIENT
608,"Twenty-eight NTG patients with progressive visual field defects/optic disc excavation, new disc hemorrhage, or field defects that threatened fixation.",PATIENT
609,"In the Women's Health Study, a randomized 2 x 2 factorial trial of aspirin and vitamin E conducted between September 1992 and March 2004, 39 876 US women aged at least 45 years and initially without previous history of cancer, cardiovascular disease, or other major chronic illness were randomly assigned to receive either aspirin or aspirin placebo and followed up for an average of 10.1 years.",PATIENT
610,Forty ASA physical status I and II adult patients scheduled for conventional pulmonary lobectomy.,PATIENT
611,Treatment with 74-Gy vs 60-Gy RT with concurrent and consolidation carboplatin/paclitaxel with or without cetuximab.,NON-PATIENT
612,Patients undergoing trabeculectomy were randomized (1:1) to receive text message reminders 3 days before appointments at 1 and 2 weeks and 1 month after surgery and free topical corticosteroid medication (US$5.30) at each visit or to standard follow-up without reminders or free medication.,NON-PATIENT
613,"Patients were randomised (1:1) to receive best supportive care plus oral placebo or erlotinib (150 mg/day) until disease progression, toxicity or death.",NON-PATIENT
614,"Neovascularization of the iris (NVI), neovascular glaucoma (NVG), disc or retinal neovascularization (NVD/NVE), preretinal or vitreous hemorrhage (PRH/VH), and nonperfusion.",NON-PATIENT
615,"Of a total of 82 included eyes in 82 patients with newly detected high-pressure open-angle glaucomas, 76 (55 capsular, 21 simple) fulfilled the 2-year follow-up with the stated number of reliable visual field examinations and were included in this analysis.",PATIENT
616,"Central corneal thickness as measured by ultrasound pachymetry (DGH-500 Pachette; DGH Technologies, Exton, PA). The CCT measurements were obtained in the morning before measuring IOP. Five measurements were taken from each eye of each patient within 5 minutes of application of anesthetic eye drops.",NON-PATIENT
617,Success rate based on IOP.,NON-PATIENT
618,"Description of population and eyes based upon clinical examination and central assessment of fundus angiography, iris photographs, and stereo color fundus photographs.",NON-PATIENT
619,"Mean intraocular pressure (IOP) was assessed at 8 AM, 10 AM, and 4 PM at week 2, week 6, and month 3. Supportive outcomes were mean and percent IOP change, percentage of patients achieving IOP <18 mm Hg or ≥30% IOP reduction, and adverse events.",NON-PATIENT
620,"Shandong Cancer Hospital and Institute in Jinan, China.",NON-PATIENT
621,"Daily oral gefitinib, either 500 mg (administered as two 250-mg gefitinib tablets) or 250 mg (administered as one 250-mg gefitinib tablet and 1 matching placebo).",NON-PATIENT
622,"Four-week, double-masked, randomized, placebo-controlled, parallel, three-center study.",NON-PATIENT
623,A total of 56 eyes of 41 patients with open-angle glaucoma or ocular hypertension were entered in the study; 46 eyes of 41 patients were eventually used for the final analysis.,PATIENT
624,"Prospective and randomized study, and in vitro experiment.",NON-PATIENT
625,"The study eyes underwent PGTP, which consisted of primary trabeculectomy, phacoemulsification, and posterior chamber IOL implantation. Adjunctive mitomycin C (MMC) (0.5 mg/ml for 1 minute) was used selectively only in patients with one or more risk factors for filtration failure of PGTP.",NON-PATIENT
